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 Precision medicine emphasizes the patient-specific formulation for treating diseases, 
especially cancer. For targeted cancer treatment, however, since the expression level of tumor 
receptors on each patient varies even for the same type of cancer, the ligand-receptor mediated 
approach does not seem promising for precision medicine. In this study, we first identified a 
tubulin-interactive peptide (TIP) from Tau protein that is a well-known microtubule binding 
protein. The TIP was attached on an up-converting nano-particle (UCNP) core with other 
functional peptides, including the SKBR-3 cell-targeting peptide that was selected via in vitro 
biopanning by our lab and cell penetrating peptide R8, to synthesize multi-functional 
nanoparticle complex CTP/TIP-UCNPs. We have demonstrated CTP/TIP-UCNPs for a potential 
tubulin interfering anti-cancer reagent, which could be specifically delivered to the breast cancer 
cells, interrupt the cellular microtubule function and finally killed the cells. To better apply the 
precision medicine on anti-breast cancer therapy, through in vivo biopanning, we first selected an 
MCF-7 breast tumor-targeting peptide, then tested the effectiveness of the as-selected peptide in 
tumor homing, and finally conjugated the peptide to a model photothermal drug, the gold 
nanorods, to achieve enhanced cancer killing efficacy. The peptides identified by phage display 
technique can guide the drug to tumors without the need of first knowing the exact receptors on 
the tumor, which will take significantly less effort to explore the patient-specific targeting 
molecules for precision medicine. However, we also developed the substitute of tumor-bearing 
model with low cost for tumor-targeting reagents discovery, the 3D cultured breast cancer cell 
spheroids, which can mimic the in vivo tumor microenvironment and have similar drug 
resistance to real tumor tissues rather than two dimensionally cultured cancer cells. The natural 
network structure of penicillium fungi was first used to develop biocompatible scaffold and 
xiii 
 
culture in vitro MCF-7 breast cancer cell spheroids. 3 advantages of our method were confirmed 
comparing to the other published 3D cell culture methods: 1. The template of the scaffold and 
the surface modification of it can be generated effortlessly; 2. Neither special devices, cell matrix 
and laboratory skill nor another type of helper cell is required for the spheroid growth; 3. The 
scaffolds have loose enough space for 3D cell spheroids to better proliferate than the same 
amount of cells growing without the scaffold in non-adherent culture dish, and also have enough 
strength to be easily transferred with a pair of tweezers. So that, the cell spheroids could be 
applied for the purpose those require multiple steps of solution changes such as gradient 
dehydration for SEM and paraffin embedding based histology analyses and phage display 
biopanning.  
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Chapter 1: Introduction  
 
1.1 General background 
Breast cancer has the second highest death rate among all the kinds of cancers for women 
in the U.S. About 12.4% of women will develop invasive breast cancer in their whole life, and 
another 3% women are projected to develop non-invasive breast cancer.1 Fortunately, since 
2002, breast cancer incidence rate started decreasing in both the U.S and Canada. The main 
reason is believed to be a reduced use of hormone replacement therapy (HRT), especially for 
women between the age of 50 to 69.2 Unlike most other type of cancers, surgical removal of 
breast tumor will permanently damage the patient’s female physique. Instead of such ineffective 
and potentially harmful surgery, my goal is to develop biocompatible nanomaterials to image, 
target and precisely kill breast cancer tumors.  
1.2 Types of breast cancer and treatments 
Breast cancer differs by the exact location of the tumor, and by the invasive types or the 
molecular subtypes.  Different breast cancer types have different incidence rates and mortality 
rates among all human races of all ages. According to the breast cancer statistics on 20133,  the 
overall incidence rate is similar between non-Hispanic white and African American women aged 
younger than 60 by 2010 and significantly higher in non-Hispanic white women than African 
American women aged elder than 60. But for the estrogen (ER)- type of breast cancer, the 
incidence rate is significant higher in African American women than non-Hispanic white of all 
age. However, for Hispanic women the incidence rate of either ER+ or ER- breast cancer is the 
lowest among all women of all age. The mortality rate of overall breast cancer from 2006 to 
2010 for African American Women was about 30.8%, which is the 7.9% higher than non-
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Hispanic white women and more than twice higher than Hispanic women. Although many 
factors might cause a woman to develop breast cancer or help her survive it, age is the most 
important factor influencing both the incidence rate and mortality rate. Including in situ and 
invasive breast cancer, the incidence rate among women aged beyond 50-year-old is three times 
higher (75.0% of 309,860 cases) than those aged younger than 50 (25% of 309,860 cases); the 
patients older than 50 have a double risk of death (30%) than younger patients (15%); among 
women aged older than 50 in comparable number of breast cancer cases,  the mortality rate of the 
ones aged over 65 is almost twice higher (18.8% of 121440 cases) than those age between 50- 
and 64- year-old (10.8% of 110980 cases).4 Without any doubt, an optimal therapy specific for 
the diagnosized breast cancer subtype will ensure the best chance of survival for the patient.  
1.3 Breast cancer targeting therapy 
In cancer targeting therapy, a medicine interferes the tumor growth, progression or spread 
through any of the following ways: i) a cytotoxin or chemo drug is specifically delivered into the 
tumor sites5-6; ii) the drug attacks a specific cancer associated molecule;7-9 or iii) the drug is only 
active or being activated in the tumor sites.10-12 Comparing to the common chemo therapy, the 
targeted cancer therapy might show an enhanced anti-cancer ability as well as possibly less side 
effect due to the precise treatment against the tumor sites. For the cancer-specific drug delivery 
approaches, the delivery system usually contains three components: the anti-cancer drugs, the 
organic vehicles or inorganic nano-carriers and tumor-targeting molecules (Figure 1.1). In some 
conditions, the nanocarriers also play the role of anti-cancer drugs such as gold-nanorods and 
quantum dots. The nano-carriers, including inorganic, organic and highly branched polymers, all 
showed one or more of these advantages: decrease of cytotoxic to normal cells, increase in the 
circulating time or half-life of the drug, controllable release, tunable size and surface properties, 
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etc. 13-16 The most important portion of the targeted cancer therapy is the tumor-targeting agent. 
Monoclonal antibody (mAb) is the most well-known cancer delivery agent with high specificity 
to tumors and many clinical approval members.17-19  Phage display-derived (antibody phage 
display, APD) mAb became another promising tumor-targeting agent with comparable tumor-
specificity as regular mAb since the first APD mAb was approved for therapeutic use in 2007.20 
Figure 1.1. Diagram of targeted cancer therapy agents (a) and schematic diagram of drug-
loading methods (b).21 Most types of agent contain three components: targeting agent, drug 
carrier and anti-cancer agent. 
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1.4 Peptide displayed phage library selection 
1.4.1 Filamentary bacteria phage biology 
Filamentary bacteria phage (Ff) including M13, fd and f1, is a type of Escherichia coli (E. 
coli) K12‐infecting phage, with the long filamentary shape (6-7 nm × 500-1000 nm) and a single 
strand DNA (ssDNA, 6407-6408 bases) genome. They share about 98% identical DNA sequence 
and very similar coat proteins, thus they can be studied and applied interchangeably. There are 5 
types of coat proteins for Ff phages: the major coat proteins pVIII (~2700 copies) and four minor 
coat proteins pIII, pVI, pVII and pIX (5 copies for each protein, Figure 1.2). 1, 22-23  
 
Figure 1.2. The structure of M13 and fd phage. 
1.4.2 Phage library and Biopanning 
All five coat proteins can be genetically engineered to display exogenous peptides, 
however pVIII and pIII are the most common position for peptide display without effecting their 
life cycle. By modifying the surface proteins of Ff phages, they could be used for many 
applications, including nanotechnology template, bio-functional nanofibers and the most 
significant contribution phage display.24-27 Phage display technique enables the application of 
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phage display library, which contains billions of phages clones randomly displaying various of 
exogenous peptides.28 For pIII displayed library, a relatively long peptide (12 to 15 residues) is 
displayed at all 5 copies of pIII proteins of phage. For pVIII display library, also called landscape 
library, the foreign peptide is displayed on every copy of pVIII protein.28 The pVIII displayed 
peptide is relatively short (8 residues at most), however the amount of them is abundant.  
During the biopanning process, billions of random peptide-displayed phages will 
competitively interact with the targets. Only those phages with high target affinity peptide will 
be selected and amplified. The biopannning process shares a similar principle as positive 
selection for T cell development and the product peptide of biopanning could be used to produce 
APD mAb. Thus, phage display biopanning is also called antibody phage display.29-30 The target 
of antibody phage display is wildly diverse, including inorganic and organic compounds, metal, 
polymers, cells, tissues and others.31-34 The most common targets of phage biopanning are 
clinical associated  biomarkers or tumor tissues. The identified peptides can be used as the target 
agent for the nanocarrier targeted cancer therapy system.  
1.5 Properties of inorganic particles 
1.5.1 Up-converting nano-particles (UCNPs) 
The up-converting nano-particles (UCNPs) is a unique type of material that convert light at 
long wave length to short wavelength. For instance, the lanthanide doped UCNPs could convert 
near-infrared (NIR) light at 980nm to visible light (Figure 1.3A).35 Since NIR can deep penetrate 
the biological tissue with low photodamage, the UCNPs are promising nanocarriers for 
photosensor drug36 or in vivo imaging37 (Figure 1.3B). 
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Figure 1.3. (A) Photo of UCNPs solution excited by laser at 980nm.35  The doped lanthanide 
element ratio for blue UCNPs is ytterbium (Yb3+): thulium (Tm3+) = 25%: 0.3%; for green 
UCNPs is Yb3+: erbium (Er3+) = 20%: 2%. (B) Illustration of the penetration depths for UV and 
NIR light.38 
For targeted cancer therapy application, the UCNPs have several advantages: i). The 
UCNPs are safe with intravenous injection dose of 15mg/kg body weight both short-term and 
long-term trails.39-41 Thus, the UCNP is an remarkable nanocarrier candidate for the exploring 
and studying unknown anti-cancer agents, or promising in vivo imaging agent for pre-clinical 
application. ii). The optical characteristic of UCNPs allows them to act as bifunctional 
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nanomaterial for in vivo study. The anti-cancer treatment and in vivo tumor imaging are possibly 
accomplished at the same time.42 iii). Surface of UCNPs can be modified by various of ligands at 
the same time, such as in vivo imaging enhancer, targeting agent, photothermal agent and others. 
It suggests that the UCNPs could be an ideal carrier candidate for multiple treatment purpose 
(Figure 1.4).43 
Figure 1.4. Typical architecture of the therapeutic UCNPs‐based composite. 43 
1.5.2 Properties of` gold nanorods 
Many types of gold nano-materials can be constructed to generate heat, including gold 
nanocages, nanorods, nanoshells and nanostars. Therefore, they are mostly employed for 
photothermal therapy (Figure 1.5).44 Except the photothermal properties of gold nano-mateials, 
each type of nano-particle has its own advantage. For example, the core-shell structure of 
nanoshells enhances the image contract;45  the nanostars have large surface area for ligand 
conjugation or absorption;46 the cavity of nanocages allow the nano-carriers to load a large 
number of drug, slow release and increase the circulating half-life of the drug.47 Overall, the 
photothermal property and other special characteristic of gold nanoparticles makes them at least 
dual targeting/ killing ability against cancer cells without needing of extra anticancer agents. 
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Comparing to those gold nano-materials, nanorods have the highest length/width ratio, which 
makes nanorods different in two following ways: i). The excitation and emission spectrum of 
nanorods is narrow;48 ii). The cellular uptake of gold nanorods is significantly low (Figure 1.6).49 
For better applying targeted cancer therapy, the relatively low cellular uptake of non-specific 
nanorods decreases the distribution of drugs in healthy tissue and protect those organs and tissues 
from side effects.  
Figure 1.5. (a) Photothermal therapy. (b) Four of the most commonly employed AuNPs for 
photothermal therapy. 44 
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Figure 1.6. The effect of shape of the nanoparticles on cellular uptake. 49  When the aspect ratio 
equals to 1, the cellular uptake of nanoparticles with 74 nm in diameter is higher them with 14 
nm indiameter. When one dimension of nanoparticles is fixed to 14 nm, the longer for the other 
dimension, the lower the cellular uptake is. 
1.6 In vitro 3D cultured cancer cell spheroids  
  2D cultured cells, which is also called monolayer cell culture, were attached on the 
surface of the culture dish. Either the cellular morphology or the cell-cell interaction is different 
from the real in vivo tumors. Comparing to 2D cell culture, in vitro 3-dimensionally growing 
cancel cell spheroids, also called in vitro tumors show higher drug resistance and 
unhomogeneous biology profile, which are much closer to the real solid tumor tissues.50-57 Thus, 
for in vitro anti-cancer drug research, 3D cultured cell spheroids are the ideal models. There are 
several methods for generating 3D cultured cell spheroids, growing cells in non-adherent surface 
cell culture dish58-60 or microfluidic platform61-63, hydrogel matrix made of collagen fibers or 
others57, 64-66, hanging drop of medium67-68 or coculture the cancer cells with endothelial cells or 
stem cells (Figure 1.7).69 
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Figure 1.7. Summary of in vitro tumor culture techniques and applications.70 
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Chapter 2 Multi-functionalized nanoparticles for cancer-targeting cell 
imaging and tubulin-interactive anti-cancer therapy 
 
2.1 Introduction 
Tubulin proteins are monomeric proteins of microtubule (MT), which is one crucial type of 
structure of cellular skeleton. By polymerizing to MTs and dispolymering to tubulins, tubulin 
proteins play an important role in most cellular activities, including plasma transportation, cell 
immigration and karyokinesis cycles. Aggressive cancer cells are high proliferated cells with 
extremely active pathological cell mitosis. Thus, many tubulin interactive reagents were 
clinically applied as anticancer drugs. Generally, the tubulin interactive reagents interfere with 
the microtubule behavior in two typical ways, inhibiting the tubulin polymerization or promoting 
it. Either way would disable the cellular MT dynamics, interrupt the cell mitosis and finally 
cause cell apoptosis.71-72 As the polymerization inhibitor, bisindole alkaloids vinblastine and 
vincristine were the first clinical used nature-produced tubulin interactive anticancer medicine 
since 1960s, which bind to β-tubulin and prevent MT assembly.73-75 On the opposite, paclitaxel, 
or taxol as it was also called, was found to promote the tubulin polymerization and show 
significant clinical activity for refractory ovarian cancer and refractory breast cancer around 
1990.76-79 Therefore, study of developing tubulin interactive agents will  improve the anticancer 
therapy in the future. 
However, the anti-tubulin type of agent influent not only the cancer cells but also the 
normal cells due to the non-specific uptake of cells, including toxicity of proliferating cells and 
neural system.80-81 Developing cancer targeting tubulin interactive anticancer agents is a 
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promising way to minimize the side effect.82 In this study, we conjugated the lanthanide-doped 
up-converting nanoparticles (UCNPs) with three functional peptides, tubulin-interactive peptide 
(TIP), cancer cell-targeting peptide (CTP), and cell penetrating peptide R883-85 to build a multi-
biofunctional nanoparticles (CTP/TIP-UCNPs). The peptide DGSIPWST were selected as 
SKBR-3 binding agents from landscape phage library biopanning in our lab86, showing 
significant cancer cell binding affinity and was used as the cancer-targeting portion of 
multifunctional nanoparticles. Five potential tubulin-binding peptides were selected from phage 
library biopanning too.87 However, none of those tubulin-interactive candidates showed 
promising microtubule-function and cell viability interference. Thus, we picked a 15 residues 
peptide VQIINKKLDLSNVVQS from the microtubule binding domains of tau protein and used 
as an cytotoxic tubulin-interactive peptide (TIP) reagent.88 Although tau is a well-known 
microtubule-associated protein, the peptide itself has never been approved or used as tubulin-
interactive anti-cancer drug in any current report. The in vitro microtubule assembly assay 
confirmed remarkable tubulin-binding ability of both TIP and TIP modified UCNPs. The further 
assays including cell viability assay, confocal-imaging and in vivo anti-tumor test determined 
that the multi-biofunctional nanoparticles CTP/TIP-UCNPs could effectively kill the breast 
cancer cells, interfering microtubule functions and inhibit the in vivo tumor growing on an 
animal model. In sum, the CTP/TIP-UCNPs showed promising specific anti-microtubule activity 
and potential to be applied as anti-cancer reagent in further preclinical research.  
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2.2 Materials and Method 
2.2.1 Cell line and chemical reagents 
Human breast cancer cells SKBR-3 (ATCC Org.) were cultured in Dulbecco's Modified 
Eagle Medium (DMEM, ATCC Org.) with 10% fetal bovine serum (Gibco Inc.) at 37℃ with 5% 
CO2.  
2.2.2 Synthesis of NaYF4: Yb, Er upconverting nanoparticles (UCNPs) 
 To synthesize NaYF4:18%Yb, 2%Er UCNPs, we modified the method described in 
several reports based on our own experience.89-90 All the chemical reagents used in this section 
were purchased from Sigma-Aldrich Inc. First, NH4F (0.37 g, 10 mmole) and NaOH (0.40 g, 10 
mmole) were mixed with 27.5 ml of oleic acid and 22.5 ml of 1-octadecene (ODE) in a 100 ml 
three-neck, heated to 110 ℃ under vacuum for at least 30 min, stirring until the solid completely 
dissolved. Then, the mixture of chloride compounds of the rare earth elements including YCl3· 
6H2O (606.72 mg, 2 mmole), YbCl3· 6H2O (174.37 mg, 0.45mmole) and ErCl3· 6H2O (19.08 
mg, 0.05mmole) were added in the above solution, kept string at 110 ℃ under vacuum until a 
clear solution was formed. And afterwards, the solution was heated to 300 ℃ under vacuum for 
30 min. The prepared UCNPs were collected washed for 3 times by acetone. Finally, they were 
dispersed in cyclohexane for storage. 
2.2.3 Preparation of UCNPs/SiO2 core/shell nanoparticles 
The concentration of as-prepared UCNPs in cyclohexane were adjusted to 0.5 mg/ml. The 
water-in-oil microemulsion was then prepared by mixing together 50 µl of IGEPAL CO-520 
(Polyoxyethylene (5) nonylphenylether, Sigma-Aldrich Inc.), 10 µl of 38% ammonia hydrate for 
1 ml of cyclohexane dispersion of UCNPs. The mixture was sonicated for 10 min and then 
vigorously stirred for about 30 min to form a stable inverted microemulsion. Afterwards, 5 µl of 
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tetraethoxysilane (TEOS, Sigma-Aldrich Inc.) were added to the mixture to initiate the 
hydrolysis reaction. After 12 h to 16 h of reaction, the silica coated UCNPs were destabilized and 
precipitated by adding acetone to the microemulsion. The nanoparticles were then washed 
repeatedly by ethanol and water, and finally dispersed into ethanol for storage. 
2.2.4 Surface modification of Silica-coated UCNPs 
The silica-coated UCNPs in ethanol were first precipitated and resuspended into 
ethanol/water mixed solvent (4:1 v/v). at the concentration of 1 mg/ml. Then, 20 µl of 38% 
ammonia hydrate, 2mg mPEG-Silane (Methosy PolyEthyleneGlycol-Silane, Biochempeg 
Scientific Inc.) and 0.5 mg Silane-PEG-COOH (Silane-PolyEthyleneGlycol-Acetic Acid) were 
added subsequently into 1 ml of the solution. The mixture was vigorously stirred for 12 h to 16 h. 
And afterwards, a wash step of ethanol was applied to remove the unbound PEG. To active the 
carbohydrate group on the surface of PEG deposited silica-coated UCNPs, the particles were 
suspended in MES buffer (0.1M of 2-(N-Morpholino) ethanesulfonic acid, PH=4) and added by 
0.03 mg NHS (N-Hydroxysuccinimide, Sigma-Aldrich Inc.) and 0.10 mg EDC (N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, Sigma-Aldrich Inc.) per 1 mg of 
particles and reacted for 15 min at room temperature. And then the active particles were 
immediately precipitated and resuspended into 1 ml of Phosphate buffered saline (PBS) and 
added by 50 µl of 5 mM desired peptide (Peptide 2.0 Inc.). The peptide conjugation was allowed 
to continue for 5 hours at 4℃. Finally, the peptide modified particles were centrifuged and 
dispersed to desired concentration in serum free cell medium. 
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2.2.5 Enzyme-linked immunosorbent assay (ELISA) for evaluating the tubulin binding 
affinity of the selected phages. 
The five tubulin-binding phages were incubated with E.coli K91 BlueKan cells and 
tetracycline overnight at 37 ˚C with shaking. Then centrifugation was applied to remove bacteria 
cells in the culture medium and the phage particles in the supernatant were purified by double 
precipitation with PEG/NaCl (3% PEG, 3.75M sodium chloride). Five liters of each type of 
phage were amplified and purified. The concentrations of phage were measured by measuring 
optical density (OD) at 269 nm. To conduct ELISA, identical number of potential tubulin 
binding phages or wild type phages were first coated on a 96-well plate. After surface blocking 
of the phages by 0.5% bovine serum albumin (BSA) solution, the biotinylated tubulin was added 
to each well and incubated with the phages for an hour followed by washing away the unbound 
tubulin with PBS for three times. Then the bound tubulin proteins were linked with streptavidin 
labeled by Alkaline Phosphatase (ALP, ThermoFisher Scientific Inc.), an enzyme that can 
quantitatively convert p-Nitrophenyl Phosphate (pNPP, ThermoFisher Scientific Inc.) to a 
soluble yellow product which can be quantified at 205 nm. Five repeats were employed for each 
type of phages to exclude the random error. 
2.2.6 Cell viability inhibition assay of TIP/CTP-UCNPs against SKBR-3 cells. 
 The AlamarBlue assay was applied for semi-quantificating the cell viability inhibition of 
TIP/CTP-UCNPs against cancer cells. SKBR-3 cells were incubated with TIP/CTP-UCNPs and 
control groups those include R8-UCNPs, TIP-UCNPs and negative control, at a series of 
concentration of 0.25, 0.5, 1.0 and 2.0 mg/ml respectively for 24 hours. And afterwards, the 
unbound particles and old medium was removed and 200 µl of pre-mixed assay medium (20 µl 
of AlamarBlue reagent was added in 180 µl of serum-free EMEM medium) were added in each 
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well and cultured at 37 °C for 3.5 to 4 hours in the cell incubator. Finally, the absorption at 570 
nm and 600 nm of each well was measured by plate reader. The cell viability was normalized by 
the negative control group. 
2.2.7 Microscopic imaging of UCNPs uptake by breast cancer cells 
 For normal microscopic images of UCNPs uptake cells, the cells were first cultured in 24 
well plate for 24 hours to perform good cell behavior. For confocal microscopy measurements, 
the cells were cultured in 8 well chamber slides. Then the test peptide modified UCNPs with 
different concentrations were added to replace the old medium and incubated with the cells at 37 ℃ 
for 16 to 24 hours. After removal of the unbound UCNPs and the old medium, the cells were 
washed for 5 times with warm PBS buffer and fixed with 4 % of paraformaldehyde (PFA, w/v, 
in PBS) for 15 min at room temperature. For immunofluorescence staining of microtubule, the 
fixed cells will be treated with 0.1 % of Triton X-100 (v/v, in PBS) for 10 to 15 min on ice to 
penetrate the cell membrane. And afterwards, 1 % of BSA (w/v, in PBS) was added into the well, 
blocking the cells for 2 hours at 4 ℃ following by adding mouse anti-α tubulin antibody (Abcam. 
Inc) and incubating at 4 °C for 12 h. After a wash step of PBS buffer for 5 times, Alexa Fluor 
555 labeled donkey anti-mouse IgG secondary antibody (Abcam. Inc) was added and incubated 
with cells for 1 h in the dark. Finally, the cells were washed with PBS for 6 times and mounted 
by cover slip with a drop of Glycerol mounting medium with 4′,6-diamidino-2-phenylindole 
(DAPI, EMS. Inc). 
2.2.8 Live and Dead assay of SKBR-3 cells 
The cells were cultured in 24 well plate for 24 hours to maintain good cellular behavior 
and then incubated with different concentration of TIP/CTP-UCNPs, TIP-UCNPs or Ctrl-UCNPs 
individually for 24 h. Then the Live/Dead cell imaging kit (ThermoFisher Scientific Inc.) was 
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employed for fluorescent stain live cells and dead cells separately. Briefly, the two components, 
Live Green and Dead Red were thawed, mixed and added to the same volume of cell medium. 
The cells were ready to image after 15 min of incubation at room temperature. 
2.3 Results  
2.3.1 Characteristics of SiO2-coated UCNPs 
The fluorescent intensity spectrum of our UCNPs showed the major peak at 540nm and the 
minor peak at 525 nm, when the UCNPs were excited by laser at 980 nm (Figure 2.1A). 
Meanwhile, strong green fluorescence can be seen (Fig. 1A inset). The TEM images of UCNPs 
and SiO2-coated UCNPs are shown in Figure 2.1B and C respectively. We demonstrated that the 
average size of uncoated spherical UCNPs or the core UCNPs was 40 ± 4 nm and the thickness 
of SiO2 shell is about 7-8 nm. 
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Figure 2.1. A: Fluorescent spectrum of UCNPs solution excited at 980 nm. Inset images: 
photographs of UCNPs under white light (left) and 980 nm laser irradiation (right). B: 
transmission electron microscope (TEM) image of uncoated sphere UCNPs. C: TEM image of 
SiO2 coated UCNPs, core/shell structure. The scale bars indicate 100 nm for both TEM images.  
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2.3.2 Evaluation of the identified tubulin binding peptide.  
The enzyme-linked immunosorbent assay (ELISA) was employed to evaluate the tubulin 
binding affinity of the selected phages (Figure 2.2A). The optical density of the final solution at 
405 nm indicated the relative tubulin binding capability of the phages. Comparing to the wild 
type phage, all the selected phages showed remarkably higher affinity to tubulin (Figure 2.2B), 
and the sequences T1, T3 and T5 were considered as the most promising tubulin binding phage 
due to the highest OD value. Then, the tubulin polymerization assay was employed to monitor 
how the selected tubulin-binding phages, T1, T3 and T5 will influence the normal process of the 
assembly of into microtubules. The polymerization process91 was tracked by measuring the 
optical density (OD) of the solutions at 340 nm. Under the experimental condition, OD340 of 0.1 
is approximately equal to a microtubule concentration of 1.0 mg/ml. Paclitaxel, which is a strong 
inducer for tubulin polymerization92-94, was also used for control experiments. It can be seen 
from the polymerization assay that the phages with T3 sequence (green line) can promote tubulin 
polymerization as well as the paclitaxel, while the promotional effect was not as significant by 
phages displaying T1 and T5 sequences. Thus, the T3 phages were considered as the best 
tubulin-interactive reagents. However, since the tubulin-binding peptides must be delivered into 
the cytoplasm to play a role in interrupting the microtubule assembly behavior, and the cell 
penetrating ability of tubulin-binding phages is unknown, the cell viability assay was applied to 
find out if the tubulin-binding phages can pass through the cell membrane to enter the cells and 
affect cell viability. SKBR-3 cells were incubated with the tubulin-binding phages or the wild 
type phages in a 96 well plate for 48 hours, followed by the assay. Two different final 
concentrations of phage were added (2×1012 and 6×1012 virions/ml). Although the T3 peptide 
displayed phages showed the strongest microtubule assembly interference. Comparing to the 
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control group in which the cells were cultured in media without any phage, neither the wild type 
nor tubulin-binding phages can affect the cell viability (Figure 2.2C and D).   
These above facts indicated: (1) Phage particles are harmless to cells even at a very high 
concentration (6×1012 virions/ml) and can be further used for in vitro or in vivo tests; and (2) 
Although the tubulin-interactive phages could significantly bind to the tubulin proteins, they 
could not interfere the cancer cell viability for following two possible reasons: i). Phages 
displaying only tubulin-interactive peptides on the side wall are not able to penetrate cell 
membrane to bind microtubules or free tubulins; ii). The interaction between the tubulin and the 
displayed peptide was not strong enough to interrupt the regular microtubule behavior due to the 
complex intracellular environment.  
Figure 2.2. (A) Table showing the sequences of five tubulin-interactive peptide candidates. (B) 
Direct ELISA to detect the affinity between tubulin-binding phages and tubulin. Compared to 
wild type fd phage (WT), all the tubulin-binding phages showed higher affinity to tubulin 
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(p<0.01). This data shows that the phage displaying T3 peptide has the highest affinity. (C) 
Tubulin-binding phage showed no cytotoxicity to SKBR-3 cells.  The cell viability was 
normalized by negative group. The final concentration of phage was 2×1012 (blue) or 
6×1012virions/ml (red). (D) The polymerization reactions in the absence of any drug (Standard) 
and in the presence of 10 µM paclitaxel and with tubulin-binding phages (displaying T1, T3 or 
T5 peptides) or wild-type (WT) phages.  
2.3.3 In vitro cell imaging with UCNPs.  
The Peg-UCNPs were modified by only TIP or CTP, or by both peptides with the molar 
ratio of 1:1. SKBR-3 cells were incubated with each kind of UCNPs, including the Peg-UCNPs, 
with the concentration of 0.2 mg/ml in the 24 wells plate for 16 hours and then the images were 
captured by using the 980 nm laser as the excitation light source (Figure 2.3). The light intensity, 
optical length and the exposure time was consistent for all the photos. As we expected, the 
uptake of PEG-UCNPs is the lowest and hardly offers the visible fluorescence image. Although 
each kind of peptide conjugated UCNPs penetrated into the cells due to the cell internalizing 
function of the R8 sequences, the CTP linked nanoparticles apparently displayed the stronger 
fluorescence than the TIP-UCNPs. It is likely that the CTP plays a role to anchor the particles 
onto the cell membrane and increase the chance of endocytosis. Additionally, the TIP/CTP 
double functionalized nanoparticles showed the brightest green light. This exciting result 
suggested that the interaction between the cellular microtubules and the TIP might help the 
UCNPs retain in the cells after the uptake.  
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Figure 2.3. The fluorescence imaging of SKBR-3 cells on the basis of 0.2 mg/ml of UCNPs. (A) 
Peg-UCNPs, (B) TIP-UCNPs, (C) CTP-UCNPs and (D) TIP/CTP-UCNPs. The scale bar 
indicates 20 μm. 
2.3.4 Cytotoxicity of CTP/TIP-UCNPs against SKBR-3 cells 
To Examine the cytotoxicity of CTP/TIP-UCNPs against the breast cancer cells, 
AlarmaBlue assay was applied to determine the half maximal inhibitory concentration (IC50) of 
it against SKBR-3 cells. The Peg-UCNPs were conjugated with different combination of four 
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peptides: tubulin-interactive peptide (TIP), cancer cell-targeting peptide (CTP), cell penetrating 
peptide R8 and a random control peptide (Ctrl, WTDSIPGSGGGRRR). To enhance the 
microtubule assembly interference of   CTP/TIP-UCNPs, the ratio of TIP: CTP: R8 was adjusted 
to 2: 1: 2. According to the relation between the molar mass and the mean diameter of UCNPs,95 
the estimated molar concentration of 1 mg/ml of UCNPs was 10 nM. Therefore, the theoretical 
ratio of peptides to particles was 500 to 1. Although the real amount of peptides attaching on the 
surface of a single particle was absolutely lower than 500, each portion of the modified peptide 
was able to functionalize the particles. For CTP-UCNPs and TIP-UCNPs, the corresponding 
portion of function peptides was replaced by control peptide. Both portions of CTP and TIP were 
replaced by control peptide for Ctrl-UCNPs. The same amount of R8 peptide were attached at 
each type of particles. For AlarmaBlue assay, the cells were incubated with Ctrl-UCNPs, TIP-
UCNPs or CTP/TIP-UCNPs at concentration of 0.25 mg/ml, 0.5 mg/ml, 1.0 mg/ml or 2.0 mg/ml 
respectively, for 24 h. The cell viability without any interference was set as 100% (Figure 2.4). 
Overall, the control particles showed no inhibition to the cell growth at all concentrations and the 
cell viability was significantly inhibited by both type of tubulin-interacting nanoparticles, TIP- 
UCNPs and CTP/TIP-UCNPs groups. The inhibition of cell growth for either tubulin-interactive 
nano-particles showed linear increasing pattern from 10-13% to 22-34% as the concentration 
increased from 0.25 mg/ml to 2.0 mg/ml. However, the difference of cell viability between TIP-
UCNPs and CTP/TIP-UCNPs groups was not significant when the concentration is as low as 
0.25 mg/ml, but became greater since the concentration was equal or higher than 0.5 mg/ml. 
When the concentration of nano-particles was as high as 2.0 mg/ml, the cell viability inhibition 
of CTP/TIP-UCNPs was significantly lower than TIP-UCNPs with the difference of 12 %. 
According to the trendline of each group, the IC50 of CTP/TIP-UCNPs against SKBR-3 cells 
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was 5.9 mg/ml that was significantly lower than 12.6 mg/ml of TIP-UCNPs and the IC50 of Ctrl-
UCNPs is incomputable. The cell viability assay exhibited the following three facts: the UCNPs 
appeared to be noncytotoxic to SKBR-3 cells; the TIP was able to inhibit the cell viability and 
the CTP could improve the cell viability inhibition of TIP.  
Figure 2.4. AlarmaBlue assay of SKBR-3 cells incubated in the presence of control or 
functionalized UCNPs at different concentration for 24 hours. The cell viability was normalized 
by the cell viability without any interference. * indicates P value between the test group to the 
corresponding control group: ** indicates P < 0.01;  *** indicates P < 0.001. 
To verify that if the cell viability inhibition of CTP/TIP-UCNPs was caused by cell death, 
SKBR-3 cells were incubated with or without 1 mg/ml of peptide modified UCNPs for 24 hours 
following by Live/Dead cell imaging stain to determine cell death (Figure 2.5). Without the 
presence of any nano-particles, dead cells were seldom found in the microscopic view.  More 
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dead cells appeared in the presence of either Ctrl-UCNPs or CTP-UCNPs with no significant 
difference between each other group. However, the significant cell death was on have only 
observed for the cells incubating in the presence of tubulin-interactive peptide modified UCNPs, 
CTP/TIP-UCNPs and TIP-UCNPs. As I expected, the Live/Dead imaging assay verified that the 
TIP modified nanoparticles could significantly kill the breast cancer cells in vitro, and 
meanwhile, the deposit of CTP could greatly enhance the cytotoxicity of TIP modified 
nanoparticles.  
Based on the previous results, we have determined that the tubulin-interactive peptide 
VQIINKKLDLSNVVQS specifically image and kill the breast cancer cells with the help of an 
imaging component UCNPs, a cell-penetrating peptide R8 and a cell-targeting peptide 
DGSIPWST. However, it is still unclear whether the TIP interfere the intracellular microtubule 
assembly to induce cell death. Therefore, the cells were imaged by confocal microscope to 
determine the tubulin polymerization and the morphological changes of cells. To prevent the cell 
detaching from the slides and to decrease the non-specific cell uptake of peptide modified 
UCNPs, the incubation time of cells and nanoparticles was reduced to 4 hours. At this time, most 
the cells were not yet in mitosis and still attached on the slide.96 The confocal microscopic 
images showed that without the presence of TIP, all SKBR-3 cells, in negative, Peg-UCNPs, 
Ctrl-UCNPs and CTP-UCNPs groups, exhibited common cell morphology and regular 
microtubule polymerization (Figure 2.6A-D). For the cells incubated with TIP-UCNPs for 4 h 
(Figure 2.6E), the microtubule filaments disappearance97-98 was observed like the effect of  
nocodazole, which binds to the tubulin dimer and inhibits tubulin assembly.97 With higher uptake 
of CTP/TIP-UCNPs due to the cell binding ability, the treating cells (Figure 2.6F) showed 
significant morphological change and microtubule depolymerization. The change of microtubule 
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structure was similar as the breast cancer cells treated by high dose of nocodazole.96, 99-100 The 
confocal microscopic images suggested that the TIP modified UCNPs could be uptake by the 
breast cancer cells and interfere the regular microtubule function by either inhibiting the 
microtubule assembly or promoting the microtubule depolymerization. The tubulin-interference 
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Figure 2.5. Microscopic images of Live/Dead cell imaging assay. The live cells were labeled by 
FITC fluorescent calcein (Green) due to the presence of ubiquitous intracellular esterase activity. 
DNA of the dead cells (Red) was indicated by Texas Red attached cell-impermeant component 
that only entered dead cells. The Scale bars indicate 100 µm. 
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Figure 2.6. Confocal-microscopic images of SKBR-3 cells those were incubated with 1 mg/ml 
of different functional peptide modified UCNPs for 4 hours. (A) no interference; (B) Peg-UCNPs; 
(C) Ctrl-UCNPs; (D) CTP-UCNPs; (E) TIP-UCNPs; (F) CTP/TIP-UCNPs. The α-tubulins were 
indicated by Alexa-Fluor 555 (Red). The nucleus was indicated by DAPI (Blue). The scale bars 
indicate 10 µm.  
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2.4 Conclusion and Discussion 
In this study, we selected a 15-residues peptide sequence VQIINKKLDLSNVVQS (TIP) 
from Tau protein, which has never been approved or applied to interrupt microtubule assembly 
individually. We have synthesized the multi-functional nanoparticles CTP/TIP-UCNPs with the 
cell-targeting peptide (CTP), TIP and cell penetrating peptide R8, which trend to be uptake by 
breast cancer cells, interfere the regular microtubule function and then kill the cancer cells. Since 
the core of the complex, UCNPs are not only a stage of the peptides but also a fluorophore, 
CTP/TIP-UCNPs can be used to image the cancer cells too. However, some questions remain to 
be studied in the future. For instance, the TIP appeared to promote the tubulin polymerization in 
microtubule assembly assay in a way similar to paclitaxel. Instead, the TIP delivered into the 
cells inhibited the tubulin polymerization similar as nocodazole according to the confocal-
microscopic images. It is possible that the TIP interacts the extracellular and intracellular tubulin 
protein in different ways. The complicated cell plasma environment might limit the aggregation 
between the nanoparticles and proteins or accelerate the microtubule degradation when it binds 
to the particles. A systematic in vivo study needs to be designed and accomplished to verify the 
anti-tumor potential of our complex particles for preclinical application in the future. 
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Chapter 3: Guiding nanomaterials to tumors for breast cancer precision 
medicine: From tumor-targeting small molecule discovery to targeted nano-
drug delivery to breast tumors 
 
3.1 Introduction 
In the recent decade, targeted drug delivery has been studied intensively in cancer 
treatment.101-104 It involves the use of tumor-recognizing molecules in the drug formulation to 
enhance drug accumulation in the cancerous tissue. This strategy can result in significantly 
enhanced cancer treatment efficacy, decreased side effects as well as reduced drug use. Up to 
date, different types of molecules with tumor affinity, such as antibodies,105-109 folic 
acid/folate,110-115 and hyaluronic acid,116-119 have been reported and employed for targeted drug 
delivery. These molecules interact preferentially with certain types of proteins that are 
overexpressed or specifically expressed at the tumor sites. Namely, in this type of tumor-
targeting approach, it requires unambiguous pre-knowledge of the corresponding tumor receptors 
that are paired with these targeting molecules.120-123 However, such strategy neglects the patient-
specific tumor difference for the same type of cancer. Ideally, a molecule targeting patient-
specific tumors should be identified and then integrated with the cancer therapeutics to achieve 
customized cancer therapy. This is the goal of precision medicine in the context of cancer 
therapy. Precision medicine is a new emerging research area that aims to provide personalized 
drug formulations or treatment plans for individual patients.124-125 It is expected that by using the 
patient-specific solution, cancer treatment can be significantly more effective. Since each type of 
cancer differs in many ways on different patients, especially on the molecular level, the tumor 
receptor-based targeted delivery strategy may not work quite well for precision medicine, as the 
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expression level of receptors may vary dramatically among different patients. This is also one of 
the reasons why the current cancer therapeutics result in low survival rate. In addition, for 
unknown types of tumor or new tumor variants on individual patients, it is practically difficult to 
explore the specific ligand-receptor pairs for them when the patient-specific receptors have not 
been identified. Here I show that without considering the unique receptors of breast tumors, I 
discovered novel peptides capable of preferentially recognizing the tumors by phage display 
technique. This is possible because in principle identification of targeting peptides by phage 
display does not require us to have prior knowledge of the target, and thus peptides affinitive to 
unknown types of tumor can be selected in a fast and cost-effective manner, allowing us to seek 
patient-specific tumor-homing peptides. I intend to demonstrate a new strategy of breast cancer 
precision medicine using MCF-7 breast cancer bearing mice as the model, where a tumor-
homing peptide customized to a specific patient is first identified without the need of knowing 
what receptors this peptide is recognizing and then linked with a cancer nanomedicine (using 
photothermal gold nanorods, AuNRs, as a model drug) to selectively inhibit tumor (Figure 3.1).  
For the first time, I demonstrate such strategy by carrying out the whole procedure from the 
discovery of tumor-homing peptides to the eventual validation of the peptide in targeted breast 
cancer therapy using the same animal model in the same lab. 
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Figure 3.1. Schematic description of the phage display-based breast cancer precision medicine. 
a) Selection of the patient-specific breast cancer-targeting peptides through in vivo phage 
display. A phage library was first injected through tail vein into the tumor-bearing mice and 
allowed to circulate for 24 h. Afterwards, tumors with preferentially bound phages were removed 
from mice and homogenized. Phages were then collected by centrifugation, amplified and used 
as input for the next round of in vivo selection. b) Coupling of the as-selected peptide with 
anticancer nanomedicines (AuNRs) to enhance their accumulation inside tumors so as to achieve 
highly efficient cancer treatment by photothermal therapy. 
3.2 Materials and Experiments 
3.2.1 Cell line and MCF-7 tumor xenograft  
Human breast cancer cells MCF-7 (ATCC Org.) were cultured in Eagle’s Minimal 
Essential Medium (EMEM, ATCC Org.) with 10% fetal bovine serum (Gibco Inc).  To generate 
tumors on the mice, 2.5- 3 × 106 cells in 0.1 ml of saline were hypodermically injected on the 
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right flank for each mouse (Athymic Nude-Foxn1nu, 3-5 weeks, female, Harlan Lab). All the 
tests in the in vivo phage display and photothermal therapy were started when the tumor reached 
0.5-0.8 cm in diameter.  
3.2.2 In vivo phage display 
The f3-15mer phage library (aka fUSE/15mer; GenBank Accession AF246445) displaying 
15-mer peptide on all five copies of pIII coat proteins at N-terminal on fd phages were provided 
as a gift from Dr. George Smith at the University of Missouri. At least 1 × 1012 transducing units 
(TU) of f3-15mer phage library were intravenously injected into each tumor-bearing mouse 
through the tail vein and allowed to circulate for 1 hour before the euthanasia by CO2 
asphyxiation. Then 20 ml of PBS was used to wash the unassociated phages by heart perfusion. 
The tumor-recognized phages were purified from the tumor homogenate and then amplified to be 
used as new input phages for the next round of selection. The tumor-homing peptide sequences 
in every round of selection were identified by phage genome sequencing from the third to fifth 
round. 
3.2.3 In vivo fluorescence imaging 
All the peptides with biotin labeled at C-terminal for conjugation with streptavidin were 
commercially purchased from United BioSystems. A linker of GGG was added to the C-terminal 
during the peptide synthesis for each peptide. The streptavidin proteins tagged with a 
fluorescence dye (Cy5) at a dye/protein ratio of 6.5 were purchased from USBiological. To 
conduct conjugation, 16 µl of 1 mg/ml streptavidin was added to 800 µl of 6.0 µM peptide saline 
solution, and the mixture was then incubated at room temperature for 3 h. Free unconjugated 
peptide was then removed by using Slide-A-Lyzer Dialysis Cassettes (10,000 MWCO, Thermo 
Inc.) according to the protocols provided with the kit. The Cy5-peptide conjugates were stored at 
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4 °C and used within 24 h after preparation. For in vivo imaging, 5 nmol of the as-prepared Cy5-
peptides conjugates dissolved in 100 μl saline was injected through tail vein of each tumor model. 
All of the mice were given anesthesia of 4% isoflurane /oxygen mixture and scanned under the 
In vivo Xtreme Imaging System (CarestreamInc.) 24 h after the injection. 
3.2.4 Synthesis of gold nanorods 
Gold nanorods were synthesized through a seed mediated process. Seed solution was 
prepared by adding 600 μl of NaBH4 (100 mM) into 10 ml mixture solution of 0.25 mM 
HAuCl4 and 0.1 M CTAB under vigorous stirring. A total of 30 ml AuNRs solution was 
prepared each time. Briefly, to a 30 ml growth solution, which contained 0.5 mM HAuCl4 and 
0.1 M CTAB, varying amounts of 4 mM AgNO3 solution and 210 μl of 78.8 mM ascorbic acid 
solution were added in sequence. After gentle shaking, 36 μl of the as-prepared gold seed 
solution was added, and the growth of AuNRs took place under room temperature for overnight. 
The resultant nanoparticles solution was considered as the as-synthesized AuNRs. 
3.2.5 Preparation of peptide conjugated tumor-homing AuNRs 
The peptides used for AuNRs conjugation were synthesized with four additional lysine 
amino acids (KKKK) at the C-terminal. It is expected that the majority of the conjugation 
reaction takes place through the amine groups at the C-terminal, leaving the –NH2 at the N-end 
free. The AuNRs with extinction band maximized at around 808 nm were synthesized according 
to the well-developed seed-mediated method in cetyltrimethylammonium bromide (CTAB). 
Conjugation of peptides onto AuNRs can be finished through a three-step surface modification. 
To begin with, 100 ml of the as-prepared AuNRs were centrifuged twice at 10,000 rpm for 10 
min, and then redispersed into 50 ml of 0.1 mM HS-PEG aqueous solution and placed overnight 
to allow the CTAB molecules on the AuNRs surface to be replaced by HS-PEG molecules. The 
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AuNRs were then centrifuged once and mixed with 50 ml of 0.1 mM HS-PEG-COOH for a few 
hours to achieve partial ligand exchange of HS-PEG by HS-PEG-COOH. Afterwards, the 
nanoparticles were subjected to another round of centrifugation and redispersed into 10 ml of pH 
6.0 MES buffer. The peptide conjugation was then initiated by activation of –COOH with EDC 
(4 mg) and NHS (6 mg) at room temperature for 15 min, followed by centrifugation at 4 oC for 
10 min. Thereafter, the nanoparticle pellet was immediately resuspended into 2 ml of 1 mM 
peptide/ salinesolution and left on a rocker shaker for 2 h under room temperature. The resultant 
peptide-conjugated tumor-homing AuNRs were about 5 mg/ml in concentration and 200 µl of 
the solution containing about 1 mg of AuNRs were used for each mouse for intravenous injection.  
3.2.6 Quantification of AuNRs tissue distribution through ICP-AES 
Peptide 1 or control peptide conjugated AuNRs (200 µl, 5 mg/ml) were intravenously 
injected into each tumor-bearing mouse (5 mice/group) through the tail vein and circulated for 1 
day to 5 days before euthanasia. The tumors and other organs including liver, kidney, heart and 
lung, were excised after heart perfusion and completely dried in a freeze-drying system. Some 
peripheral blood was collected before heart perfusion as well. Afterwards, all these tissues were 
weighed and then digested completely by freshly prepared aqua regia. Finally, the solution was 
diluted with large amount of water, filtered and used for Inductively coupled plasma atomic 
emission spectroscopy (ICP-AES) quantification.  
To track the gold concentration in peripheral blood, 20 µl of blood was collected from 
suborbital space of 5 anesthesia mice each time at 3 min, 20 min, 1 h, 4 h, 7 h, 12 h, 24 h and 48 
h after injecting either peptide conjugated AuNRs or PEG modified AuNRs. The gold was then 
digested and quantified following the same procedures as above. 
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3.2.7 Photothermal treatment of MCF-7 tumor  
20 tumor-bearing mice were randomly separated into four groups. Mice in each group were 
injected intravenously with target peptide-AuNRs, control peptide-AuNRs, PEG-AuNRs and 
saline respectively. The amount of AuNRs was 1 mg per mouse. Twenty-four hours after 
injection and under general anesthesia, all the mice were irradiated at the tumor site by 808 nm 
laser for 5 min at a power density of 2.25 W/cm2. The laser spot size is about 1 cm in diameter. 
After laser irradiation, the mice were housed for another 20 days, after which the tumors were 
measured in dimensions and were then taken out of the mice and weighed. The tumor volume 
was calculated by the following equation: Volume= length × width2/2. 
3.2.8 haematoxylin and eosin (HE) staining  
For HE staining, tumors were excised from mice 3 h after laser treatment and then placed 
immediately into 10% fresh formalin solution and soaked for 24 h. The fixed tumors were 
embedded in paraffin block following standard procedures. Thereafter, they were cut into 5 µm 
thick sections and mounted onto glass slides. Before imaging, the slices were deparaffinated and 
stained subsequently with hematoxylin and eosin staining solutions. The imaging was carried out 
on Eclipse Ti microscope system (Nikon Instruments Inc.). 
3.3 Results  
3.3.1 Biopanning against in vivo MCF-7 tumors 
Briefly, in vivo phage display was carried out by several rounds of affinity test against MCF-7 
tumors in vivo. In the first round, a phage library, which contains billions of phage clones with 
each displaying a unique 15-mer peptide at the five copies of minor coat protein (pIII) of the 
phage, was injected intravenously into tumor-bearing mice. After an hour, the mice were 
sacrificed and the tumors were excised and homogenized. Tumor-associated phages (output 
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phages) were extracted from tumor homogenate and used as an input for the next round of 
selection. Similarly, in the rest rounds of selections, output from the previous round was 
employed as an input for the next round and injected intravenously into a new tumor-bearing 
mouse. In this work, a total of 5 rounds of selection were conducted. It is expected that phages 
appear in the output of subsequent rounds should have higher tumor affinity. Hence, I randomly 
isolated some output phage clones in round 3, 4 and 5. Since the DNA inside the phage 
genetically encodes the peptides displayed on the surface of the phage, the DNA of the tumor-
associated phage clones was sequenced to identify the sequences of 15-mer peptides (Tables 3.1, 
3.2, 3.3 and 3.4).  A total of 246 colonies were identified from 3-5 rounds of in vivo selection and 
the top 12 identified peptides with the number of repeats no less than 2 after the 5th round are 
listed in Table 1. Our following studies were mainly focused on the top 5 peptides with the 
highest occurrence frequency, namely AREYGTRFSLIGGYR (peptide 1), 
PKAFQYGGRAVGGLW (peptide 2), PVRYGFSGPRLAELW (peptide 3), 
RNVPPIFKEVYWIAQ (peptide 4) and RTLIRMGTGAHAFAV (peptide 5), as they are more 
likely to have higher affinity to MCF-7 tumors than the rest of the peptides.   Among these 
peptides, peptide 1 has the highest occurrence frequency, indicating that peptide 1 has the highest 
tumor affinity. 
Sequence Count  (30 seq. total) Sequence 
Count  
(30 seq. total) 
AREYGTRFSLIGGYR 1 PSVPVFRGRFFQVDY 1 
AVVSSGGALYXRIVR 1 PVIAIPPSFANMFLF 1 
FAFSPCPLESNVIGC 1 PWSSRPWYLQFLGAA 1 
FSLGVSSVIFSPVSA 1 RLVCWRLGCVSPMGS 1 
FVFPRPNAY* 1 RPPVVDAAHFGASRW 1 
GHSPRCSSSFVRCEA 1 RQQDGRLIYTTASVR 1 
GQDVRIRNEVNQYGL 1 SEELLVESSAIRSRE 1 
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GVQVPFSGGSSLLGM 1 SNPGLFVSGYWRLFP 1 
GVSEDASVQHYYRSP 1 TRLECFSAGWRLSAC 1 
LRMGLCSDQIRLSCA 1 TRVYWAPVSEGDVSP 1 
MFRTFVGRSSNAVVG 1 VSSQHGXGREVNSAV 1 
MQSVSGWFPWESVAY 1 VYASPASIPWSFAGL 1 
NAVRVAFWSVPLYPF 1 YFTTPATLLPFGVGT 1 
NAVRVAFWSVPLYXF 1 YRVREPQLFCCEGPD 1 
PGGGANFLLSPFSGG 1 PSVPVFRGRFFQVDY 1 










ACAIGCXQANGLALV 1 PFPVSSRVVPRFTAV 1 
AGGGGPTVGDDRVRR 1 PIGVFWDDLLIRH 1 
ALGRGRVVGVRLVSL 1 PKAFQYGGRAVGGLW 3 
AREYGTRFSLIGGYR 3 PKAXQYGGRAVGGLW 1 
AVYPLLVICLLGRFW 1 PVQSLYAIGGVSLDT 1 
DGLRVGXWDAVSX 1 PWSSILVGRSSSLLS 1 
DKCVRRXILFMLVLM 1 QDFFAFCGGLAAVCG 1 
DVLYRFGHSSVVFPG 1 RCSSFAMCGSIVPGS 1 
FPYTRVPHFGNVHSS 1 RFPSASWSFSGHAAT 1 
GASILGGXXGXXP* 1 RGAPFFISVSERAFR 1 
GLAPVGSHSATPRPW 1 RSSGAVXNGVGVSALG 1 
GLDLLHTTWRCCAPP 1 SGTGLXYPSWTAGSS 1 
GPVVLPWPLFDGHLS 1 SGVHSYLAXRPVRL 1 
GRXRLGVVSVLSXDG 1 SIGEMPSGLVTLSST 1 
GTLKVGMMCSLGACLG 1 SNPGLFVSGYWRLFP 1 
HRWMPHVFAVRQGAS 1 SRHVRSLGNLGDVSVG 1 
KTWPXLVPGSASGRA 1 TSASTSVFIXRASST 1 
LDPRRASFHIGRAAP 1 TTCLDFFNRPEVFWG 1 
LFTPFFSCHEFRCWD 1 TYHSVVWSEPVVWS 1 
LGRAGQSYPSFARGL 1 VRCEGVLINGDRCGL 1 
LGRARDRLSIQFPHF 1 VSSQHGXGREVNSAV 1 
LRFISVAVAGNLSWA 1 WSNRMPPLFTXWYX 1 
LRPPVAGMSVARVYG 1 YFTTPATLLPFGV* 1 
LVRALPLWPLVGPV 1 PFPVSSRVVPRFTAV 1 
MCAVRDPAFSRS* 1 PIGVFWDDLLIRH 1 
MPLRFFXPSXGPLAP 1 PKAFQYGGRAVGGLW 3 
PFARAPVEHHDVVGL 1 PKAXQYGGRAVGGLW 1 
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AHPPLASVWHVSVPL 1 PKAFQYGGRAVGGLW 7 
ALESSGSVPSRDLPP 1 PLRYGPSRSRLDEVW 1 
AREYGTRFSLIGGYR 7 PMLGPHLCVSEFCGR 1 
ARIGFASGSRPYVSS 1 PNRNYLPNTSMDGSR 1 
ASSFSVSEVSVVRRV 1 PPDSFSRGYRVRDTF 1 
ASSVPYVDANWSYNR 1 PPQTISGKARYLPSV 1 
AVFDGSLCVPGFYSC 1 PRAASIFRAGHVSML 1 
AVTPQNPYGIQRDRR 1 PSALRVKGFTVVSRS 1 
AYGLVVPDLPAMPSL 1 PVRYGFSGPRLAELW 3 
CAGFQSRQVAL* 1 QADGPNSVVRPFTLT 2 
CSGCAPGFRSERAIR 1 QPVSAVPLCRLHCRS 1 
DRYLPINGVSMFGVP 2 QPWHPGVYGVASSVA 1 
DSALRVSRWRLSHSV 1 RAPRSAPGIFVFRSF 1 
DSSSLGNSSGSRGWR 1 RERIHSPGSTQILFL 1 
EGLFSFPRGASE* 1 RFGFSATWDQSNLLL 1 
FAFSPCPLESNVIGC 1 RGFLSDLHALASRDR 1 
FGHIIPSRFDRLSLG 1 RNVPPIFKEVYWIAQ 3 
FGRIPSPLAYTYSFR 1 RRVP* 1 
FLLTGLQHATSSGFR 1 RSDHLGVGPASASRYG 1 
FSDSFVTGVWAPSRP 1 RSFAYAAAPTSFPWV 2 
FSSGGTSYRLRHIPF 1 RSLSHGGRWGPGYAI 1 
FSVSFPSLPAPPDRS 1 RSPWSDFYASASRGP 1 
FVFPRPNAY* 1 RTLIRMGTGAHAFAV 3 
FVRHYLLGGQGSLPR 1 RVLFLVAALAIGSLA 1 
GAKPGLGPRAHLGGV 1 RVLGRDGSVFYELAA 1 
GALHQTRPVGPAFAW 1 RVNFLFKPSVIFNAP 1 
GAPGAFFGSVRDVVPRR 1 RVPPRYHAKISPMVK 1 
GAPLSANFNNPAFWR 1 RVQSTILSGLRGFSS 1 
GAVDFVSLYAAATVA 1 RVTHHAFLGAHRTVG 1 
GAYPSLDFPRAPSFG 1 RYRPVFPGFEETLPR 1 
GDAFGFFPPFRTMG 1 SDHSPTQSQRASHDA 1 
GFTDVHLHLPGNSHR 1 SDWFPTACFDCRSVR 1 
GGAVFPEYPLARAFL 1 SGASRNSAFWAVSVA 1 
GGPLVSPLSEDARPW 1 SGAYSSFRPSHHTTR 1 
GKGEVSLYSLGSPGM 1 SGLCRYESPSGRPSC 1 
GLHGATPAHRLFHTG 1 SGNSAIWPRVRLLHG 1 
GSGAVSPPLWAARGR 1 SGYMTSALIRPSRFP 1 
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GSGTAYMMRPSLGPD 1 SKKPQSSNEGYRIAD 1 
GTRAVLVVGLDALSA 1 SKTFQYGGRAIEGPW 1 
GVGHVRAGHLRSVGI 1 SLPHLAPFGTTFFGP 1 
GWSHFYRSPNFLRIQ 1 SPPLAPYGGTRVGLT 1 
HAALSLPWYRINSVY 1 SPPLAPYGGTRVGLTG 1 
HGSLGLGWPGHTSVR 1 SSGFRDAFRGWDGSA 1 
HKAIQHGGRAVGGAW 1 SSVA* 1 
HPTTSYSTSVFSWGW 1 STFFGFVGNSIVRPW 1 
HVSGYVSRFDRSVGA 1 STSGVLSSILHVVSV 1 
HVTCVHSVSSLRSIV 1 SVGCPVVGTVGYLRCG 2 
IPLLVNLPHLPRAAL 1 SVLHPALDFTSLA 1 
IPVQFSTIDFVAASY 2 SVVXLRTRHFSTDSA 1 
KVGVALVGP* 1 TGSVLSRFASGRLAP 1 
LAGVQMSLRSLDTRR 1 TGTVVQVADPFAGGH 1 
LFLNSHDDDRSFLSS 1 TNVPPISNDA* 1 
LGAHVVLSGSSDFFP 1 TPFVFRAGRFFLHAG 1 
LGGAGPFFGLGLVES 1 TRLECFSAGWRLSAC 1 
LLGELPPTPRSPRLW 1 VCSPVFSPFCKMSVA 1 
LPSIGPWEPXPDALS 1 VFGATSVVRDLYSLR 1 
LRPPVAGMSVARVYG 1 VFRRVDTAVYKPSYP 1 
LRSLVSYSGGHNYSG 1 VGAASFYLERGSRXS 1 
LTLSHPHWVLNHFVS 1 VLERSRRVLGGAAKV 1 
LVGTLLGAHGFVAIP 1 VRINNCIGFDSNCTS 1 
LVSRLTPCDLSFYAC 1 VRMFDYGVPRRAVYG 2 
MAAWLPHSYSITRLL 1 VRVTPSFFREPSGFV 1 
MHFGPGFGH* 5 VTATAAQPGDAFIGV 1 
NAAGYNSRVVTLPLF 1 WFPTHPFWTYSSWTG 1 
PAQSNFVTWGYNVAV 1 WRYRLVYALLAMLTI 1 
PFARAPVEHHDVVGL 1 YSRVLSSSSYRFFDR 1 
PGHSLGKLSVLHSFF 2   
Table 3.3. 162 sequences were randomly picked and identified from the 5th round of in vivo 
biopanning. The * marker indicates the incomplete peptides displayed on particular phages, 
which might be the result of either the failure of sequencing or the insertion of a stop codon into 
the fusion DNA sequence. 
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Table 3.4. Summary of peptide sequences and frequencies in the 3rd to 5th round of in vivo 
phage display against MCF-7 tumors *. * Only peptides having total colonies no less than 2 are 
included in this table. Rd = round of biopanning; cln = total phage colonies. 
3.3.2 Live in vovo imaging of tumor-bearing mice 
For in vivo imaging, the 5 peptides were conjugated to streptavidin with a Cy5 fluorescent 
tag and were injected into mice through tail vein. In vivo imaging was carried out 24 h later. For 
comparison, a random peptide, KGYGVGLRFPAWQGA, was used as a control peptide. The 
amount of peptides accumulated at the MCF-7 tumors is judged by the fluorescence intensity, 
and the stronger fluorescence indicates more peptide accumulation. As shown in Figure 3.2, all 
of the 5 selected peptides have exhibited significantly higher tumor accumulation in comparison 
to the control peptide. Among them, peptide 1 showed the strongest fluorescence intensity, 
suggesting that it has the best tumor-homing capability. In addition, peptide 2 presented slightly 
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lower fluorescence intensity compared to peptide 1, which is consistent with the fact that peptide 
1 has slightly higher occurrence frequency than peptide 2 (Table 3.4). Thus, peptide 1 is chosen 
for the following targeted drug delivery tests. 
 
Figure 3.2. In vivo imaging for the detection of selective accumulation of tumor-homing 
peptides at the MCF-7 tumors. Peptides were first labelled with biotin at the C-terminal, and then 
conjugated to Cy-5 tagged streptavidin. Images were taken 24 h after the intravenous injection of 
5 nmol of peptides (100 µl in saline). All of the images were taken under the same parameters, 
thus the intensity difference represents the actual difference of peptide accumulation at the tumor 
sites. 
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3.4.3 Characteristics of peptide modified AuNRs 
I then conducted in vivo experiments to test the excellence of the selected peptides in tumor 
targeting. First, I employed the in vivo imaging system to verify peptide accumulation at tumor sites. 
Second, I conjugated the peptides to gold nanorods (AuNRs, Figure 3.3), a well-known photothermal 
reagent,126 to find out the effectiveness of the selected peptides in enhancing the targeted delivery 
of drugs to cancerous tissues. 
 
Figure 3.3. TEM image (left) and UV-Vis spectrum (Right) of the as-synthesized AuNRs used 
for the photothermal treatment.  
The peptide-assisted in vivo drug delivery was tested by quantification of nanoparticles’ tissue 
distribution as well as the effectiveness of photothermal treatment on MCF-7 tumor-bearing mice. To 
conduct the test, peptide 1 was first conjugated with AuNRs at the C-terminal through a well-developed 
method, in which the as-synthesized cetyl trimethylammonium bromide (CTAB) coated AuNRs were first 
replaced by HS-PEG-COOH, followed by peptide conjugation through the EDC/NHS chemistry (see 
experimental section).127-128 The resultant nanoparticles are termed Peptide-AuNRs. The 
hydrodynamic radius of the CTAB coated AuNRs, PEG coated AuNRs and peptide conjugated 
AuNRs is 40.8 ± 2.1 nm, 44.3 ± 2.5 nm and 47.0 ± 2.4 nm, respectively (Figure 3.4), suggesting 
the successful conjugation of peptides onto the AuNRs.  
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Figure 3.4. Dynamic Light Scattering (DLS) measurement of AuNRs with different surface 
ligands. The effective hydrodynamic radii are (a) 40.8 ± 2.1 nm for the as-synthesized CTAB-
AuNRs, (b) 44.3 ± 2.5 nm for the PEG functionalized AuNRs, and (c) 47.0 ± 2.4 nm for the 
peptide functionalized AuNRs. 
3.4.4 In vivo biodistribution of tumor-homing AuNRs 
For quantitative studies, 1 mg of Peptide-AuNRs (200 µl, 5 mg/ml) per mouse was used for 
intravenous injection. I first monitored for 48 h the in vivo blood circulation of AuNRs. I discovered that 
the half-life (t1/2) of the Target-AuNRs in the blood is about 16 h (Figure 3.5), and the value for the 
control peptide conjugated AuNRs (Control-AuNRs) is about 18 h; both are comparable to the previously 
reported t1/2 of PEG coated AuNRs.129 For in vivo tissue distribution study, the nanoparticles were 
allowed to circulate for five different periods of time (1 day, 2 days, 3 days, 4 days and 5 days). 
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At the end of each time point, mice were sacrificed and the organs were then freeze dried, 
weighed, and digested. Finally, the concentration of gold in each organ was quantified by the 
Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES). The Control-AuNRs 
were used as a control. In the presence of the tumor-homing peptide, the tumor uptake of AuNRs 
after 1 day circulation is 63% higher than that of the case with control peptide and it remained to 
be 61%-83% higher during the whole period of five-day monitoring (Figure 3.6). This result 
confirms that peptide 1 selected from the in vivo phage display can result in significantly 
enhanced drug delivery to the MCF-7 tumors. The distribution of peptide-AuNRs in other 
healthy organs is either less than or comparable to that of the Control-AuNRs. It is worth noting 
that the gold content in liver in the target group is 56% lower than that in the control group on 
day 1, and remained to be 22-44% lower in the following 4 days, suggesting that modification of 
AuNRs with the tumor targeting peptides can effectively reduce the non-specific AuNRs uptake 
by livers.   
Figure 3.5. Blood circulation of AuNRs. 1.0 mg of tumor targeting peptide conjugated AuNRs 
(green) or control peptide conjugated AuNRs (blue) were injected intravenously. To track the 
gold concentration in peripheral blood (represented as the mass of gold per ml of blood), 20 µl of 
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blood was collected from suborbital space of the mouse each time at 3 min, 20 min, 1 h , 4 h, 7 h, 
12 h, 24 h and 48 h after injection,  and immediately added into 200 µl of freshly prepared aqua 
regia. The concentration of AuNRs was quantified by ICP-AES. 
 
Figure 3.6. Organ distribution of AuNRs. Mice were sacrificed 1 day, 2 days, 3 days, 4 days and 
5 days after the intravenous injection of 1 mg of AuNRs. Target group was the group injected 
with peptide 1 conjugated AuNRs whereas control group was the one injected with control 
peptide conjugated AuNRs. Gold concentration was calculated as mass permillage of Au in 1 
gram of the corresponding tissue. The inset chart shows the percentage increase (in tumor, 
represented as positive values) or decrease (in liver, represented as negative values) of gold 
content in target group when compared to the control group on different days. The data indicate 
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that conjugation of our selected peptide 1 onto AuNRs can effectively increase their uptake by 
tumors but decrease their uptake by livers. 
3.4.5 Tumor targeting photothermal treatment 
The photothermal treatment was conducted 24 h after injection because the concentration 
of peptide-AuNRs in tumors is maximized at this time point according to the ICP-AES based 
biodistribution study. During the treatment, MCF-7 tumors were irradiated directly by a 808 nm 
laser at a power density of 2.25 W/cm2 for 5 min. Figure 3.7 shows photographs of tumors and 
the corresponding average tumor volumes in each group 20 days after the photothermal therapy. 
One can see that the size and volume of the tumors in the targeting group (AuNRs functionalized 
with peptide 1) is significantly smaller than those in the other groups. In fact, two of the tumors 
in this group were destructed so severely that it was hard to collect any tumor tissue even after 20 
days following the treatment. The development of tumors treated by non-targeting AuNRs, 
modified with PEG and control peptide, has also been retarded, although not as significant as 
that in the targeting group. This is because even without the assistance of targeting peptide, 
AuNRs can still be delivered to tumors through the passive targeting mechanism.  
Hematoxylin and Eosin (HE) staining study further illustrates the death of tumor cells as a 
result of photothermal treatment (Figure 3.7c). Tumors used for this study were collected from 
mice 3 h after the laser treatment. For control tumors without AuNRs (Saline group), both 
apoptosis and necrosis, the two typical cell death mechanisms, are barely found in the tumor 
cells, suggesting that the laser power density used for the photothermal treatment was safe to 
normal tissues. For tumors in the target group (Target-AuNRs), however, the classic necrosis 
characters, including karyolysis, nuclear swelling and extensive pale eosinophilic cytoplasm are 
all observed, indicating contiguous cell necrosis upon acute injury caused by photothermal 
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treatment. In addition, the apoptosis characters such as nuclear pyknosis, hypereosinophilic 
cytoplasm and apoptotic bodies were also seen, which are indications of programmable cell 
death following the laser treatment. In contrast, such damages on the other two AuNRs groups 
(PEG-AuNRs and Control-AuNRs) were not as significant. Overall, our photothermal 
investigation is in accordance with the study of organ distribution of AuNRs by ICP-AES, 
namely, the in vivo selected targeting peptides, when conjugated onto AuNRs, can indeed result 
in enhanced delivery and accumulation of AuNRs at the tumor sites, which further leads to the 
remarkably improved efficiency in the photothermal cancer therapy.  
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Figure 3.7. Photothermal treatment of MCF-7 tumors. (a) Photographs of tumors taken out from 
the mice 20 days after the photothermal therapy (For the target-AuNRs group, only two animals 
had visible tumors); (b) Average tumor volume before and 20 days after the treatment; (c) 
Images of HE stained sections of tumors obtained 3 h after 808 nm laser treatment. Target-
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AuNRs: AuNRs modified with peptide 1; PEG-AuNRs: PEG modified AuNRs; Control-AuNRs: 
AuNRs modified with a control peptide; Saline: saline only and without AuNRs. Comparing to 
the normal nucleus of cancer cells in the control tumor, contiguous cell necrosis is determined by 
the extensive pale eosinophilic cytoplasm (typically highlighted by dashed ovals) as well as 
karyolysis and nuclear swelling (typically highlighted by solid ovals). The cells apoptosis with 
the presence of nuclear pyknosis, hepereosinophilic cytoplasm (typically highlighted by arrows) 
and apoptotic bodies (typically highlighted by arrow heads) are marked. The normal tumor tissue 
area in each AuNRs treated group is also circled by angled dash frames. 
3.4 Conclusion and Discussion 
Phage display can be carried out both in vitro and in vivo. Phage library is allowed to 
interact cancer cells in the culture media in the in vitro phage display whereas it is intravenously 
injected into animals and circulated in blood stream to enable the discovery of phages homing to 
tumors in the in vivo phage display. In principle, in vivo selection against tumors should be more 
target-specific and more effective for clinic applications, as the peptides were selected under 
conditions similar as the physiological environment. So far, none of the groups has studied the 
discovery of tumor-targeting peptides using in vivo phage display and then tested the use of such 
peptides in in vivo homing and destruction of tumors, all using the same animal models and in 
the same lab.130-132 Most of the reported studies were based on peptides reported previously by 
others, rather than selected through exactly the same tumor model in the same work, thus these 
peptides cannot be considered as patient-specific. Hence, these works did not meet the 
requirement of precision medicine. In particular, for MCF-7 breast cancer, such study was 
reported exclusively based on peptides selected through in vitro phage display.133-136 In addition, 
although I only demonstrated the concept of phage display-based breast cancer precision 
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medicine by using photothermal treatment, the same procedures can be readily applied to other 
cancer therapeutics, such as chemo-, gene and photodynamic therapies. 
In summary, I have demonstrated a new strategy of breast cancer precision medicine by 
using the MCF-7 breast cancer mice model. In this strategy, a patient specific tumor-targeting 
peptide was first identified through in vivo phage display. Our in vivo imaging study showed that 
these peptides can actively target MCF-7 tumors. By conjugating the as-selected peptides with 
the model drug, AuNRs, enhanced accumulation of the nanomedicine to the tumors was 
observed by the ICP-AES measurement, which further leads to improved cancer killing 
efficiency. 
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Chapter 4: 3D multiple cell spheroids in silica coated fungi network scaffolds 
 
4.1 Introduction 
According to the cancer fact sheet of World Health Organization in 2018, cancer was the 
second global leading cause of death and caused about 9.6 million deaths.  A developed tumor 
model is desired for anti-cancer research. In vitro 3-dimensionally growing cancel cell spheroids 
can mimic the complex in vivo tumor microenvironment and retain an in vivo cancer cell 
phenotype with a similar solid structure like tumor tissues.50-53 Studies of multicellular cancer 
spheroids confirmed that the biological profile of 3D cultured cancer cells is closer to in vivo 
tumors comparing to 2D cultured cells, including cell proliferation and resistance to anti-cancer 
therapy.54-57 Thus, 3D cultured cell spheroids are the ideal model for studying the physiology of 
cancer and anti-cancer drug screening as a non-invasive alternate to animal tumor models. For 
generating 3D cultured cell spheroids, non-adherent surface cell culture dish58-60 such as bacterial 
culture dish, microwell non-adherent cell culture plate or microfluidic platform61-63 is the most 
popular device to employ. To culture the cells in space limited gel matrix of collagen fibers57, 64-
66, the hanging drop technique67-68 or coculture the cancer cells69 with endothelial cells is another 
common way to have the cells grown into multicellular spheroids. However, using either way to 
culture cell spheroids requires special devices consuming or advanced experimental skill. In 
addition, all those scaffold-free isolated cell spheroids or cell-seeded in hydrogel or 
microparticles are hard to identify, operate or transfer without a microscope. So that the 3D 
cultures cell spheroids have been rarely used for paraffin embedding histology and phage-
antibody selection.137 
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In this research, I first used the natural network structure of Penicillium fungi to build 
silica-based biocompatible branched scaffolds effortlessly. MCF-7 cancer cells will develop 
attached cell spheroids growing on the scaffold within 3 days, showing higher cell viability than 
those grow freely on non-adherent surface. The fibers of a scaffold are naturally connected as a 
single colony of fungi. Thus, the scaffolds could be easily transferred by clipping the edge of it 
without losing any fiber and the cells attached on it. Consequently, I first applied phage-antibody 
selection against in vitro tumors and paraffin embedding histology of cell spheroids. A total of 
four promising in vitro tumor binding peptides were identified by employing Ph.D.-12 phage 
peptide display library biopanning against MCF-7 cell spheroids on silica-coated fungi network 
scaffolds. 
4.2 Material and method  
4.2.1 Cell line and 3D cell spheroids generation  
Human breast cancer cells MCF-7 (ATCC Org.) were cultured in Eagle’s Minimum 
Essential Medium (EMEM, ATCC Org.) with 10% fetal bovine serum (Gibco Inc).  To generate 
3D cell spheroids, 2.5×103 to 2×104 cells in 2-5 µl medium were seeded into a piece of dry 
scaffold and then cultured in 96 well plate. Transfer the cell loaded scaffold into a new well with 
fresh medium to discard the unattached cells at the second day after cell-loading. The same 
number of cells were seeded into ultra-low attachment 96 well plates without scaffolds as a 
control. The cell viability was evaluated by AlarmaBlue assay (BioRed Inc.). The morphology of 
cell spheroids was imaged on an Eclipse Ti microscope system (Nikon Instruments Inc.) for both 
light images and phase contract images. 
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4.2.2 Preparation of silica coated Penicillium fungi network scaffolds    
The Penicillium colony were seeded into lysogeny broth (LB) broth and gently shaken at 
100-120 RPM for 2-3 days at room temperature to form network spheres 5mm in diameter. The 
fungi spheres were fixed with 4% PFA for 12 hours and autoclaved in water to completely kill 
the fungi. The sterile fungi spheres were gradient dehydrate by 20%, 35%, 50 %, 65% and finally 
80% (v/v) ethanol/water solution. To coat silica layer on the surface of the fungi mycelium, the 
fungi spheres were soaked in 75-85% (v/v) ethanol/water solution with 200 µl TEOs and 300 µl 
38%-40% ammonia hydrate and gently shaken overnight. After 3 steps of 80% ethanol washing, 
the same step of silica-coating will be repeated for two more time to assure enough silica deposit 
for long-term cell culture. Then, the silica coated spheres were washed, gradient re-rehydrated 
and soaked with water, frozen rapidly in liquid nitrogen and finally dried in a freeze-drying 
system (). To avoid possible bacteria contamination, the scaffolds will be exposed under 
ultraviolet (UV) light for 45 min before cell seeding. 
4.2.3 Light microscopy and phase contract microscopy 
The cell spheroids were directly observed under the microscope (Nikon Instruments Inc.). 
An area of 1mm × 1mm was imaged under the phase ring, the detailed area of 225 µm × 225 µm 
inside the phage contract image was pictured by normal light microscope. For better observation 
of the cell spheroids growing on the scaffold, the whole sample will be removed from the 96 well 
plate and place in a well of 24 well plate before it was imaged by light microscope. 
4.2.4 Cell viability assay of cell spheroid growing with or without scaffolds. 
 The AlamarBlue assay was applied for comparing and semi-quantificating the cell 
viability between the cell spheroids growing on the scaffolds to those growing without the 
scaffold. The assay was repeated for 4 times, at day 1, day 3, day 5 and day 7 respectively for 5 
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repeating wells of cells. In another word, the cell proliferation profile of a group of wells was 
monitored every two day for a week. Briefly, at each time point, 200 µl of pre-mixed assay 
medium (20 µl of AlamarBlue reagent added in 180 µl of serum-free EMEM medium) were 
placed in each well of a new 96 well plate. The cell spheroids on one scaffold in one well was 
transferred into a well of pre-mixed assay medium and cultured at 37 °C for 3.5 to 4 hours and 
then transferred back to the 96 well plate filled with fresh medium and kept culturing in the cell 
incubator. For AlamarBlue assay on free cell spheroids, 180 µl out of 200 µl of the old medium 
was removed and replaced by 180 µl of fresh serum-free medium and then 180 µl of the medium 
was removed again. Thus, 99% of the old medium and serum was removed from the well, 20 µl 
of serum-free medium remained in the well. 180 µl of pre-mixed assay medium (20 µl of 
AlamarBlue reagent added in 160 µl of serum-free EMEM medium) was added into each well of 
free cell spheroids. The plate was incubated at 37 °C for the exact same time as the cell spheroids 
on the scaffold were. 150 µl of the assay medium out of the total volume for both groups was 
transferred into a new 96 well plate and measured the absorption at 570 nm and 600 nm. The 
remain assay medium in the cell culture well was removed in the similar way above. 
4.2.5 Scanning electron microscopy (SEM) and Energy-dispersive X-ray spectroscopy (EDS) 
The cell spheroids were fixed with 4% PFA PBS buffer for 20 min, following by gradient 
dehydration using from 20% (v/v) to 100% ethanol/ water solution with concentration increment 
of 10%. Then the samples will be dried by critical point drying (CPD), attached on the specimen 
holder under the microscope to make sure the major area of cell spheroids growing is upward 
and sputtering coated with gold. The images and X-ray EDS were performed by NEON high 
resolution scanning electronic microscopy (Zeiss, Thornwood, NY). The component of gold was 
excluded from the weight calculation. 
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4.2.6 In vitro 3D multi-cell spheroids targeting peptide selection by phage library 
biopanning 
1 × 1012 transducing units (TU) of Ph.D.-12 phage display peptide library (E8110S 
BioLabs.Inc) were added into a 24 well plate with an empty scaffold and incubated for 1 h at 
37°C to remove the scaffold and environment binding phages. The unbound phages were 
transferred into a new well with the cell spheroid loaded scaffold to interact with the cells for 1 h 
at 37°C. The scaffold was washed 10 times to remove the unbound phage. The spheroid-binding 
phages were then eluted from the scaffold. Additionally, cell penetrating phages were eluted by 
lysing the cell spheroids. The cell lysis releases the cell-penetrating phages. Both types of 
binding phages were amplified separately and used as the input phage for the next round of 
biopanning. After the third round of biopanning, the binding phage colonies were randomly 
picked and sequenced to identify the potential tumor-homing peptide.  
4.3 Results  
4.3.1 Structure of silica-coated Fungi scaffold. 
The Penicillium mycelium sphere can grow over 3 cm long in diameter within 4-5 days in 
LB broth. To control the fungi to grow slowly is a key factor to have the fungi sphere grown with 
impact enough network of fibers. So that, instead of shaking the fungi at 220 RPM and 37℃, the 
fungi were cultured at room temperature and less than 150 RPM shaking speed. According to our 
experience, the fungus sphere with the size of 0.7-0.8 cm in diameter has the best fiber density 
and intensity of construction to provide network surface for cell attachment and suitable space 
for cell growth. Due to dehydration process for silica coating, the average diameter of silica-
coated fungus spheres is 6.3± 0.3 mm that is 15% smaller than 7.4± 0.7 mm, which is the 
average diameter of the fungus spheres before silica coating (Figure 4.1A and 4.1B). The SEM 
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image showed the scaffold is composed by numbers of fibers with the average diameter of 1.5 ± 
0.4 µm (Figure 4.1C and 4.1D). The detailed SEM image of an open-end fiber indicated that the 
fibers of scaffold are hollow (Figure 4.1E). X-ray EDS result (Figure 4.2) confirmed the silica 
layer on the fiber surface with the silicon (Si) weight ratio of 10.6 %, the weight of gold caused 
by sputtering coating has been excluded. The peak of carbon (C) is excluded from the spectrum 
due to its dominating high counts. After incubating the empty scaffold in cell culture medium for 
7 days, the silicon weight ratio decreased to 7.6%, which was still able to support the scaffold 
structure and the cell growth. 
Figure 4.1. Fungus template branched silica scaffolds. (A) Fixed fungus spheres with average 
diameter of 7.4±0.7mm soak in sterile water. (B) Silica-coated fungus spheres with average 
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diameter of 6.3±0.3mm soak in sterile water. (C and D) SEM images of the surface of the fungus 
template branched silica-coated scaffold. The average diameter of the silica coated fiber is 
1.5±0.4 µm. (E) detailed SEM image of an open-end fiber of silica-coated scaffold. 
Figure 4.2. EDS spectrum of empty silica-coated scaffold at day 0 before incubation and at day 
7 after incubation with EMEM. The peak of C is not included. The data table shows the weight 
distribution of C, O and Si.  
4.3.2 Size shrinkage in pre-SEM process 
The SEM images showed that the cells have formed spheroids with the diameter range of 
35-135 µm at day 3 after cell-seeding (Figure 4.3). However, the shrinkage of mammal cells 
during the dehydration and drying process for SEM is unignorable without using osmium 
tetroxide, which is extremely toxic and high-risk to use.138 The shrinkage range of the mean 
diameter of mammal cells and tissues is from 25% to 45% according to the related literature. In 
this study, I measured and compared the average size of both single cells and cell spheroids 
between LM and SEM images. The cell spheroids are significantly smaller in SEM image than 
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them in LM image with the shrinkage range from 34% to 48% (the average is 43 ± 6%) 
according to Figure 4.4A and B showing SEM image and LM image of the identical area of cell 
spheroids (the same sample of cell spheroids at day 7 after 1×104 cells loaded in Figure 4.3). The 
single cell has the average diameter of 15 ± 3 µm in phase contract microscope image (Figure 
4.4D), which is 38% larger than the average diameter of 9 ± 2 µm in SEM image (Figure 4.4C). 
Overall, the size shrinkage of single cell and cell spheroid in our pre-SEM process in our 
procedure mostly located in the range of 35%- 45%. Therefore, the calculated diameter range of 
the cell spheroids at day 3 is actually from 60 µm to 240 µm. The size of cell spheroid on the 
scaffold acquired from SEM image in the following discussion, including the dimeter and 
volume, were recalculated.  
- 60 - 
 
Figure 4.3. (A and B) SEM and LM images of the same sample of cell spheroids growing on the 
scaffold. The LM image was pictured right before the pre-SEM process. (C and D) SEM and 
phase contract microscope images show single cells respectively. 
4.3.3 Statistics of 3D cultured MCF-7 cell spheroids. 
The cell spheroids growing circumstance in non-adherent well plate was monitored for 7 
days post-cell-seeding (Figure 4.5). The cell spheroids growing circumstance on the scaffold at 
day 3 and day7 post-cell-seeding was showed in SEM images (Figure 4.4). Some cell spheroids 
started to form at 24 hours post-cell-seeding, most of them were smaller than 100 µm in diameter. 
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Either the size or the amount of cell spheroids increased as the time went or as the number of 
cell-seeding increased.  
Figure 4.4. SEM images of MCF-7 cell spheroids growing on silica-coated fungi network 
scaffolds at day 3 and day 7 after loading cells of 2.5×103, 5×103, 1×104 and 2×104 on the 
scaffold respectively. The side containing most of the cell spheroids were displayed by adjusting 
the specimen stage. All the scale bars indicate 500 µm. For each image, the inset image in red 
frame showed the detailed information of the area highlighted with red square. The red square 
area is 250 µm × 250 µm. 
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Figure 4.5. Phase contrast images of cell spheroids growing in Corning ultra-low attachment 
surface 96 well plate for 7 days. The bars indicate 200 µm. The inset image in each individual 
image is the zoom in view of area highlighted with green square. The green square area is 225 
µm × 225 µm. 
To evaluate the efficiency of cell spheroids forming with the scaffolds, I compared the size 
distribution for 2 × 104 cells being cultured for 7 days, between them growing with the scaffold 
and them growing without the scaffolds. The SEM images of cell spheroids growing on the 
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scaffold (Figure 4.6) showed two types of growing manners. One was that the cells trended to 
form cell spheroids in larger scale, up to 500 µm in diameter. However, the amount of cell 
spheroids is low (Figure 4.6A to D). This manner was found in the scaffolds those were loaded 
with high concentrated cell solution (2 × 104 cells in 2-3 µl of medium). The other manner is that 
the cells trended to form hundreds of relatively equal sized spheroids (Figure 4.6E to H). For this 
manner, 2 × 104 cells were loaded within 5 µl of medium. According to the two manners, I 
supposed that the cells prefer to stay at the certain spot and interact with the surrounding cells 
once they had attached on the scaffold, rather than to migrate. The size distribution statistic 
between cell spheroids growing with and without scaffold showed the comparable result (Figure 
4.7).  
Figure 4.6. SEM images of cell spheroids growing on silica-coated scaffold for 7 days after cell-
seeding with 2 × 104 cells. (A) shows cells aggregating and growing into a few large cell 
spheroids; (B, C and D) show the zoom in views of the labeled areas highlighted with white 
squares in A, respectively; (E) shows cells evenly distributing on whole scaffold and forming 
hundreds of small uniform cell spheroids. (F, G and H) show the zoom in views of the labeled 
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areas highlighted with white squares in E, respectively. Some of the zoom in images were 
captured at different stage tilt angle, so that did not show identical images in the corresponding 
highlight area.  
Figure 4.7. Statistic of size distribution for the cell spheroids with or without scaffold being 
cultured for 7 days. Only the cell spheroids having the largest diameter longer than 50 µm are 
included.  
4.3.4 Cell viability assay of 3D cultured MCF-7 cell spheroids 
To evaluate the cell proliferation growing on the scaffold, AlamarBlue assay was applied 
as a semi-quantification for the cell viability of the spheroids with or without the scaffolds 
(Figure 4.8). The cell viability of the spheroids growing on the scaffolds are significantly higher 
than those growing without scaffolds in most control groups, especially for the groups have 
larger amount of cell seeding. Based on our best knowledge, the possible reason is that the 
scaffolds provide more space 3-dimensionally rather than the bottom of the well. Another 
advantage of using the scaffold is that beyond the cell density limitation of the 96- well plate, 
over 5×104 cells could be seeded on a single piece of scaffold and formed numerous of cell 
- 65 - 
 
spheroids (Figure 4.9) for some specific type of purpose, like in vitro tumor derived tumor 
xenograft. 
 Figure 4.8. Comparation of AlarmaBlue assay between in vitro cell spheroids with or without 
the presence of scaffolds. The relative AlarmaBlue level is normalized by the one for 2.5 × 103 
cells without scaffold at day 1. All the comparation between two corresponding groups has P 
value less than 0.05. ** indicates P<0.01. The inset table shows the t-test comparison of the cell 
viability, for the same amount of cells growing for the same days. 
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Figure 4.9. Microscopic images of 5×104 cells growing on scaffold for 7 days. Some cell 
spheroids are indicated by arrows. 
4.3.5 Phage-antibody selection  
Phage-antibody selection, also known as phage biopanning is a promising way to screen 
target-specific peptides out of billions of random peptides efficiently. This technique has been 
applied to find ligand for targeting therapy and specially to develop human antibody phage 
display-derived (APD) mAb since the first full human APD mAb were made for therapeutic use 
in 2007. However, this technique has never been applied in vitro tumor targeting ligand selection 
for the following possible reason. The free cell spheroids could be easily lost during the wash 
step every round. After 10 repeats of the washing steps, the best targeting phage candidates 
might have been lost in the first round of biopanning. The character of the silica coated fungi 
network scaffold makes phage biopanning against in vitro tumor much easier to accomplish than 
using the free cell spheroids. So, in this study, I first employed phage biopanning against in vitro 
MCF-7 tumors and identified a 12-residue peptide sequence with excellent binding affinity to the 
tumors. After 4 rounds of phage biopanning, 4 targeting peptide sequences SYPSNALSLHKY, 
TLGLRPVPVATT, SEPQNIWQYLRN and SYWYEASSYTGV with the highest frequency 
were selected as the in vitro tumor targeting peptide (Table 4.1). The peptide with the highest 
tumor affinity should be verified by phage titer and IHC of cell imaging.    
 Peptide Sequence Count (201 colonies total) Frequency 
1 SYPSNALSLHKY 11 5.5% 
2 TLGLRPVPVATT 7 3.5% 
3 SEPQNIWQYLRN 6 3.0% 
4 SYWYEASSYTGV 6 3.0% 
5 TLNVPPAKRSLS 5 2.5% 
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6 WGVTKPIRTSTL 4 2.0% 
7 MKAHHSQLYPRH 4 2.0% 
8 TISAFTSFMPTN 3 1.5% 
9 WGLTAQVPESRH 3 1.5% 
10 YPSAHHSLMRPA 3 1.5% 
11 GSAARTISPSLL 3 1.5% 
12 HSTLLNHTTGVL 3 1.5% 
13 IPWSPTRIIHAQ 3 1.5% 
14 NLWATQPPSHHV 3 1.5% 
15 NYLPHQSSSPSR 2 1.0% 
16 SSHSSASVSPKT 2 1.0% 
17 SSMPINSPATRQ 2 1.0% 
18 SYASRHLPLLSS 2 1.0% 
19 ISPSHLFHQAVK 2 1.0% 
20 TYNYDMPLRGRA 2 1.0% 
21 FQARWEPPRLLQ 2 1.0% 
22 APPITSVLFPYL 2 1.0% 
23 AAHRVGGFNYHM 2 1.0% 
Table 4.1. Summary of peptide sequences and frequencies in both 3rd and 4th rounds of Ph.D.-12 
phage display against in vitro MCF-7 tumors. Only peptides having total colonies no less than 2 
are included in this table.  
4.4 Conclusion and Discussion 
In this study, I have first applied the natural structure of fungi Penicillium to effortlessly 
make a cell-safe scaffold for culturing 3D in vitro tumors. The method has a low cost and 
requires no advanced skills. The cells formed a comparable number of spheroids with a similar 
size on the scaffold as them growing in commercial non-adherent culture dish. The cell viability 
assay indicated enhanced cell proliferation on the scaffold, most likely because the scaffold 
could provide more space for cell growth. Another advantage of our new scaffold is that the 
unique structure allowed itself to be easily transferred in different solutions. Therefore, the in 
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vitro tumors could be used for complex protocol such as paraffin embedding based histology and 
phage biopanning. In vitro tumors were first employed for phage-antibody selection in this study 
and four tumor-binding peptide candidates were identified. Tumor-homing analysis should be 
evaluated in vitro and in vivo in the future. 
  
- 69 - 
 
References 
1. Rakonjac, J.; Bennett, N. J.; Spagnuolo, J.; Gagic, D.; Russel, M., Filamentous 
bacteriophage: biology, phage display and nanotechnology applications. Current issues in 
molecular biology 2011, 13 (2), 51-76. 
2. Yusuf, S.; Anand, S., Hormone replacement therapy: a time for pause. CMAJ : Canadian 
Medical Association journal = journal de l'Association medicale canadienne 2002, 167 (4), 357-
9. 
3. DeSantis, C.; Ma, J.; Bryan, L.; Jemal, A., Breast cancer statistics, 2013. CA: a cancer 
journal for clinicians 2014, 64 (1), 52-62. 
4. DeSantis, C. E.; Fedewa, S. A.; Sauer, A. G.; Kramer, J. L.; Smith, R. A.; Jemal, A., 
Breast Cancer Statistics, 2015: Convergence of Incidence Rates Between Black and White 
Women. Ca-Cancer J Clin 2016, 66 (1), 31-42. 
5. Lee, J. H.; Nan, A., Combination drug delivery approaches in metastatic breast cancer. 
Journal of drug delivery 2012, 2012, 915375. 
6. Din, F. U.; Aman, W.; Ullah, I.; Qureshi, O. S.; Mustapha, O.; Shafique, S.; Zeb, A., 
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J 
Nanomed 2017, 12, 7291-7309. 
7. Kossai, M.; Duchemann, B.; Boutros, C.; Caramella, C.; Hollebecque, A.; Angevin, E.; 
Gazzah, A.; Bahleda, R.; Ileana, E.; Massard, C.; Vielh, P.; Soria, J. C.; Besse, B., Antitumor 
activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug 
development programs (Phase I trials) at Gustave Roussy. Lung Cancer 2015, 89 (3), 306-10. 
8. Wheler, J.; Hong, D.; Swisher, S. G.; Falchook, G.; Tsimberidou, A. M.; Helgason, T.; 
Naing, A.; Stephen, B.; Janku, F.; Stephens, P. J.; Yelensky, R.; Kurzrock, R., Thymoma 
Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR 
Inhibitors and Molecular Analyses. Oncotarget 2013, 4 (6), 890-898. 
- 70 - 
 
9. Yang, Y.; Ding, L.; Wang, P., Dramatic response to anti-PD-1 therapy in a patient of 
squamous cell carcinoma of thymus with multiple lung metastases. Journal of thoracic disease 
2016, 8 (7), E535-7. 
10. Yu, P.; Yu, H.; Guo, C.; Cui, Z.; Chen, X.; Yin, Q.; Zhang, P.; Yang, X.; Cui, H.; Li, Y., 
Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive 
micelles. Acta biomaterialia 2015, 14, 115-24. 
11. Lee, E. S.; Kim, J. H.; Sim, T.; Youn, Y. S.; Lee, B. J.; Oh, Y. T.; Oh, K. T., A feasibility 
study of a pH sensitive nanomedicine using doxorubicin loaded poly(aspartic acid-graft-
imidazole)-block-poly(ethylene glycol) micelles. J Mater Chem B 2014, 2 (9), 1152-1159. 
12. Talelli, M.; Iman, M.; Varkouhi, A. K.; Rijcken, C. J.; Schiffelers, R. M.; Etrych, T.; 
Ulbrich, K.; van Nostrum, C. F.; Lammers, T.; Storm, G.; Hennink, W. E., Core-crosslinked 
polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials 
2010, 31 (30), 7797-804. 
13. Zhang, Y.; Huang, Y.; Li, S., Polymeric micelles: nanocarriers for cancer-targeted drug 
delivery. AAPS PharmSciTech 2014, 15 (4), 862-71. 
14. Mohajer, G.; Lee, E. S.; Bae, Y. H., Enhanced intercellular retention activity of novel 
pH-sensitive polymeric micelles in wild and multidrug resistant MCF-7 cells. Pharmaceutical 
research 2007, 24 (9), 1618-27. 
15. Yuan, Y.; Cai, T.; Xia, X.; Zhang, R.; Chiba, P.; Cai, Y., Nanoparticle delivery of 
anticancer drugs overcomes multidrug resistance in breast cancer. Drug delivery 2016, 23 (9), 
3350-3357. 
16. Bangham, A. D., Liposomes: the Babraham connection. Chemistry and physics of lipids 
1993, 64 (1-3), 275-85. 
17. Kontermann, R. E., Immunoliposomes for cancer therapy. Current opinion in molecular 
therapeutics 2006, 8 (1), 39-45. 
- 71 - 
 
18. Marty, M.; Cognetti, F.; Maraninchi, D.; Snyder, R.; Mauriac, L.; Tubiana-Hulin, M.; 
Chan, S.; Grimes, D.; Anton, A.; Lluch, A.; Kennedy, J.; O'Byrne, K.; Conte, P.; Green, M.; 
Ward, C.; Mayne, K.; Extra, J. M., Randomized phase II trial of the efficacy and safety of 
trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 
2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. 
J Clin Oncol 2005, 23 (19), 4265-4274. 
19. Robert, N.; Leyland-Jones, B.; Asmar, L.; Belt, R.; Ilegbodu, D.; Loesch, D.; Raju, R.; 
Valentine, E.; Sayre, R.; Cobleigh, M.; Albain, K.; McCullough, C.; Fuchs, L.; Slamon, D., 
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with 
trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J 
Clin Oncol 2006, 24 (18), 2786-92. 
20. Lee, C. M.; Iorno, N.; Sierro, F.; Christ, D., Selection of human antibody fragments by 
phage display. Nat Protoc 2007, 2 (11), 3001-8. 
21. Peer, D.; Karp, J. M.; Hong, S.; FaroKHzad, O. C.; Margalit, R.; Langer, R., 
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2 (12), 751-760. 
22. Smith, G. P.; Petrenko, V. A., Phage display. Chem Rev 1997, 97 (2), 391-410. 
23. Kehoe, J. W.; Kay, B. K., Filamentous phage display in the new millennium. Chem Rev 
2005, 105 (11), 4056-4072. 
24. Krag, D. N.; Shukla, G. S.; Shen, G. P.; Pero, S.; Ashikaga, T.; Fuller, S.; Weaver, D. L.; 
Burdette-Radoux, S.; Thomas, C., Selection of tumor-binding ligands in cancer patients with 
phage display libraries. Cancer Res 2006, 66 (15), 7724-33. 
25. Sarikaya, M.; Tamerler, C.; Schwartz, D. T.; Baneyx, F. O., Materials assembly and 
formation using engineered polypeptides. Annu Rev Mater Res 2004, 34, 373-408. 
26. Huang, W.; Petrosino, J.; Palzkill, T., Display of functional beta-lactamase inhibitory 
protein on the surface of M13 bacteriophage. Antimicrobial agents and chemotherapy 1998, 42 
(11), 2893-7. 
- 72 - 
 
27. Lee, S. K.; Yun, D. S.; Belcher, A. M., Cobalt ion mediated self-assembly of genetically 
engineered bacteriophage for biomimetic Co-Pt hybrid material. Biomacromolecules 2006, 7 (1), 
14-7. 
28. Sunderland, K. S.; Yang, M.; Mao, C., Phage-Enabled Nanomedicine: From Probes to 
Therapeutics in Precision Medicine. Angewandte Chemie 2017, 56 (8), 1964-1992. 
29. Hammers, C. M.; Stanley, J. R., Antibody phage display: technique and applications. J 
Invest Dermatol 2014, 134 (2), 1-5. 
30. Takaba, H.; Takayanagi, H., The Mechanisms of T Cell Selection in the Thymus. Trends 
Immunol 2017, 38 (11), 805-816. 
31. Yang, M.; Sunderland, K.; Mao, C., Virus-Derived Peptides for Clinical Applications. 
Chem Rev 2017, 117 (15), 10377-10402. 
32. Li, Y. J.; Whyburn, G. P.; Huang, Y., Specific Peptide Regulated Synthesis of Ultrasmall 
Platinum Nanocrystals. J Am Chem Soc 2009, 131 (44), 15998-15999. 
33. Cao, B. R.; Yang, M. Y.; Mao, C. B., Phage as a Genetically Modifiable 
Supramacromolecule in Chemistry, Materials and Medicine. Accounts of chemical research 2016, 
49 (6), 1111-1120. 
34. Naik, R. R.; Jones, S. E.; Murray, C. J.; McAuliffe, J. C.; Vaia, R. A.; Stone, M. O., 
Peptide templates for nanoparticle synthesis derived from polymerase chain reaction-driven 
phage display. Adv Funct Mater 2004, 14 (1), 25-30. 
35. Wilhelm, S.; Hirsch, T.; Patterson, W. M.; Scheucher, E.; Mayr, T.; Wolfbeis, O. S., 
Multicolor upconversion nanoparticles for protein conjugation. Theranostics 2013, 3 (4), 239-48. 
36. Li, C.; Liu, J.; Alonso, S.; Li, F.; Zhang, Y., Upconversion nanoparticles for sensitive and 
in-depth detection of Cu2+ ions. Nanoscale 2012, 4 (19), 6065-71. 
37. Weissleder, R., A clearer vision for in vivo imaging. Nat Biotechnol 2001, 19 (4), 316-7. 
- 73 - 
 
38. Chen, W.; Chen, M.; Zang, Q.; Wang, L.; Tang, F.; Han, Y.; Yang, C.; Deng, L.; Liu, Y. 
N., NIR light controlled release of caged hydrogen sulfide based on upconversion nanoparticles. 
Chem Commun (Camb) 2015, 51 (44), 9193-6. 
39. Abdul Jalil, R.; Zhang, Y., Biocompatibility of silica coated NaYF(4) upconversion 
fluorescent nanocrystals. Biomaterials 2008, 29 (30), 4122-8. 
40. Xiong, L.; Yang, T.; Yang, Y.; Xu, C.; Li, F., Long-term in vivo biodistribution imaging 
and toxicity of polyacrylic acid-coated upconversion nanophosphors. Biomaterials 2010, 31 (27), 
7078-85. 
41. Sun, Y.; Feng, W.; Yang, P.; Huang, C.; Li, F., The biosafety of lanthanide upconversion 
nanomaterials. Chemical Society reviews 2015, 44 (6), 1509-25. 
42. Lin, M.; Zhao, Y.; Wang, S.; Liu, M.; Duan, Z.; Chen, Y.; Li, F.; Xu, F.; Lu, T., Recent 
advances in synthesis and surface modification of lanthanide-doped upconversion nanoparticles 
for biomedical applications. Biotechnology advances 2012, 30 (6), 1551-61. 
43. Tian, G.; Zhang, X.; Gu, Z. J.; Zhao, Y. L., Recent Advances in Upconversion 
Nanoparticles-Based Multifunctional Nanocomposites for Combined Cancer Therapy. Advanced 
materials 2015, 27 (47), 7692-7712. 
44. Riley, R. S.; Day, E. S., Gold nanoparticle-mediated photothermal therapy: applications 
and opportunities for multimodal cancer treatment. Wiley interdisciplinary reviews. 
Nanomedicine and nanobiotechnology 2017, 9 (4). 
45. Loo, C.; Lowery, A.; Halas, N.; West, J.; Drezek, R., Immunotargeted nanoshells for 
integrated cancer imaging and therapy. Nano Lett 2005, 5 (4), 709-11. 
46. Qiu, P. H.; Yang, M. Y.; Qu, X. W.; Huai, Y. Y.; Zhu, Y.; Mao, C. B., Tuning 
photothermal properties of gold nanodendrites for in vivo cancer therapy within a wide near 
infrared range by simply controlling their degree of branching. Biomaterials 2016, 104, 138-144. 
- 74 - 
 
47. Xia, Y.; Li, W.; Cobley, C. M.; Chen, J.; Xia, X.; Zhang, Q.; Yang, M.; Cho, E. C.; 
Brown, P. K., Gold nanocages: from synthesis to theranostic applications. Accounts of chemical 
research 2011, 44 (10), 914-24. 
48. Huang, X.; El-Sayed, M. A., Gold nanoparticles: Optical properties and implementations 
in cancer diagnosis and photothermal therapy. Journal of Advanced Research 2010, 1 (1), 13-28. 
49. Chithrani, B. D.; Ghazani, A. A.; Chan, W. C. W., Determining the size and shape 
dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6 (4), 662-668. 
50. Kim, J. B., Three-dimensional tissue culture models in cancer biology. Seminars in 
cancer biology 2005, 15 (5), 365-77. 
51. Kumar, H. R.; Zhong, X. L.; Hoelz, D. J.; Rescorla, F. J.; Hickey, R. J.; Malkas, L. H.; 
Sandoval, J. A., Three-dimensional neuroblastoma cell culture: proteomic analysis between 
monolayer and multicellular tumor spheroids. Pediatr Surg Int 2008, 24 (11), 1229-1234. 
52. Holliday, D. L.; Brouilette, K. T.; Markert, A.; Gordon, L. A.; Jones, J. L., Novel 
multicellular organotypic models of normal and malignant breast: tools for dissecting the role of 
the microenvironment in breast cancer progression. Breast cancer research : BCR 2009, 11 (1), 
R3. 
53. Smalley, K. S.; Lioni, M.; Noma, K.; Haass, N. K.; Herlyn, M., In vitro three-
dimensional tumor microenvironment models for anticancer drug discovery. Expert opinion on 
drug discovery 2008, 3 (1), 1-10. 
54. Antoni, D.; Burckel, H.; Josset, E.; Noel, G., Three-dimensional cell culture: a 
breakthrough in vivo. International journal of molecular sciences 2015, 16 (3), 5517-27. 
55. Edmondson, R.; Broglie, J. J.; Adcock, A. F.; Yang, L. J., Three-Dimensional Cell 
Culture Systems and Their Applications in Drug Discovery and Cell-Based Biosensors. Assay 
Drug Dev Techn 2014, 12 (4), 207-218. 
- 75 - 
 
56. Lv, D.; Hu, Z.; Lu, L.; Lu, H.; Xu, X., Three-dimensional cell culture: A powerful tool in 
tumor research and drug discovery. Oncology letters 2017, 14 (6), 6999-7010. 
57. Chen, L.; Xiao, Z.; Meng, Y.; Zhao, Y.; Han, J.; Su, G.; Chen, B.; Dai, J., The 
enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for 
modeling of cancer and anti-cancer drugs. Biomaterials 2012, 33 (5), 1437-44. 
58. Zanoni, M.; Piccinini, F.; Arienti, C.; Zamagni, A.; Santi, S.; Polico, R.; Bevilacqua, A.; 
Tesei, A., 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to 
enhance the biological relevance of data obtained. Scientific reports 2016, 6. 
59. Weiswald, L. B.; Bellet, D.; Dangles-Marie, V., Spherical cancer models in tumor 
biology. Neoplasia 2015, 17 (1), 1-15. 
60. Napolitano, A. P.; Dean, D. M.; Man, A. J.; Youssef, J.; Ho, D. N.; Rago, A. P.; Lech, M. 
P.; Morgan, J. R., Scaffold-free three-dimensional cell culture utilizing micromolded 
nonadhesive hydrogels. BioTechniques 2007, 43 (4), 494, 496-500. 
61. Albanese, A.; Lam, A. K.; Sykes, E. A.; Rocheleau, J. V.; Chan, W. C. W., Tumour-on-a-
chip provides an optical window into nanoparticle tissue transport. Nat Commun 2013, 4. 
62. Esch, E. W.; Bahinski, A.; Huh, D., Organs-on-chips at the frontiers of drug discovery. 
Nat Rev Drug Discov 2015, 14 (4), 248-260. 
63. Sabhachandani, P.; Motwani, V.; Cohen, N.; Sarkar, S.; Torchilin, V.; Konry, T., 
Generation and functional assessment of 3D multicellular spheroids in droplet based 
microfluidics platform. Lab on a chip 2016, 16 (3), 497-505. 
64. Dhiman, H. K.; Ray, A. R.; Panda, A. K., Characterization and evaluation of chitosan 
matrix for in vitro growth of MCF-7 breast cancer cell lines. Biomaterials 2004, 25 (21), 5147-
54. 
65. de la Puente, P.; Ludena, D., Cell culture in autologous fibrin scaffolds for applications in 
tissue engineering. Experimental cell research 2014, 322 (1), 1-11. 
- 76 - 
 
66. Ekaputra, A. K.; Prestwich, G. D.; Cool, S. M.; Hutmacher, D. W., The three-
dimensional vascularization of growth factor-releasing hybrid scaffold of poly (epsilon-
caprolactone)/collagen fibers and hyaluronic acid hydrogel. Biomaterials 2011, 32 (32), 8108-
8117. 
67. Tung, Y. C.; Hsiao, A. Y.; Allen, S. G.; Torisawa, Y. S.; Ho, M.; Takayama, S., High-
throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 2011, 
136 (3), 473-478. 
68. Falkenberg, N.; Hofig, I.; Rosemann, M.; Szumielewski, J.; Richter, S.; Schorpp, K.; 
Hadian, K.; Aubele, M.; Atkinson, M. J.; Anastasov, N., Three-dimensional microtissues 
essentially contribute to preclinical validations of therapeutic targets in breast cancer. Cancer 
medicine 2016, 5 (4), 703-10. 
69. Baze, A.; Parmentier, C.; Hendriks, D. F. G.; Hurrell, T.; Heyd, B.; Bachellier, P.; 
Schuster, C.; Ingelman-Sundberg, M.; Richert, L., Three-Dimensional Spheroid Primary Human 
Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells. Tissue engineering. 
Part C, Methods 2018, 24 (9), 534-545. 
70. Katt, M. E.; Placone, A. L.; Wong, A. D.; Xu, Z. S.; Searson, P. C., In Vitro Tumor 
Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. Frontiers in 
bioengineering and biotechnology 2016, 4, 12. 
71. Kingston, D. G. I., Tubulin-Interactive Natural Products as Anticancer Agents. J Nat 
Prod 2009, 72 (3), 507-515. 
72. Butler, M. S., Natural products to drugs: natural product-derived compounds in clinical 
trials. Nat Prod Rep 2008, 25 (3), 475-516. 
73. Gueritte, F., Anticancer agents from natural products. 2 ed.; CRC press: 2011. 
74. Svoboda, G. H.; Johnson, I. S.; Gorman, M.; Neuss, N., Current status of research on the 
alkaloids of Vinca rosea Linn. (Catharanthus roseus G. Don). Journal of pharmaceutical 
sciences 1962, 51, 707-20. 
- 77 - 
 
75. Noble, R. L.; Beer, C. T.; Cutts, J. H., Role of chance observations in chemotherapy: 
Vinca rosea. Annals of the New York Academy of Sciences 1958, 76 (3), 882-94. 
76. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T., Plant antitumor 
agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from 
Taxus brevifolia. J Am Chem Soc 1971, 93 (9), 2325-7. 
77. Schiff, P. B.; Fant, J.; Horwitz, S. B., Promotion of microtubule assembly in vitro by 
taxol. Nature 1979, 277 (5698), 665-7. 
78. Mcguire, W. P.; Rowinsky, E. K.; Rosenshein, N. B.; Grumbine, F. C.; Ettinger, D. S.; 
Armstrong, D. K.; Donehower, R. C., Taxol - a Unique Antineoplastic Agent with Significant 
Activity in Advanced Ovarian Epithelial Neoplasms. Ann Intern Med 1989, 111 (4), 273-279. 
79. Holmes, F. A.; Walters, R. S.; Theriault, R. L.; Forman, A. D.; Newton, L. K.; Raber, M. 
N.; Buzdar, A. U.; Frye, D. K.; Hortobagyi, G. N., Phase II trial of taxol, an active drug in the 
treatment of metastatic breast cancer. Journal of the National Cancer Institute 1991, 83 (24), 
1797-805. 
80. Bates, D.; Eastman, A., Microtubule destabilising agents: far more than just antimitotic 
anticancer drugs. Brit J Clin Pharmaco 2017, 83 (2), 255-268. 
81. Jordan, M. A.; Wilson, L., Microtubules as a target for anticancer drugs. Nature Reviews 
Cancer 2004, 4 (4), 253-265. 
82. Calvaresi, E. C.; Hergenrother, P. J., Glucose conjugation for the specific targeting and 
treatment of cancer. Chemical science 2013, 4 (6), 2319-2333. 
83. R, M.; K, S.; H, H., Effects of the properties of short peptides conjugated with cell-
penetrating peptides on their internalization into cells. Sci Rep. 2015, 5 (12884). 
84. IA, K.; K, K., High density of octaarginine stimulates macropinocytosis leading to 
efficient intracellular trafficking for gene expression. J Biol Chem. 2006, 281 (6), 3544-51. 
- 78 - 
 
85. S, V.; SD, L., Recent developments in peptide-based nucleic acid delivery. . Int J Mol Sci. 
2008, 9 (7), 1276-320. 
86. Abbineni, G.; Modali, S.; Safiejko-Mroczka, B.; Petrenko, V. A.; Mao, C., Evolutionary 
selection of new breast cancer cell-targeting peptides and phages with the cell-targeting peptides 
fully displayed on the major coat and their effects on actin dynamics during cell internalization. 
Molecular pharmaceutics 2010, 7 (5), 1629-42. 
87. Cao, B.; Mao, C., Identification of microtubule-binding domains on microtubule-
associated proteins by major coat phage display technique. Biomacromolecules 2009, 10 (3), 
555-64. 
88. Kolarova, M.; Garcia-Sierra, F.; Bartos, A.; Ricny, J.; Ripova, D., Structure and 
pathology of tau protein in Alzheimer disease. International journal of Alzheimer's disease 2012, 
2012, 731526. 
89. Liu, C.; Wang, H.; Li, X.; Chen, D., Monodisperse, size-tunable and highly efficient 
beta-NaYF4:Yb,Er(Tm) up-conversion luminescent nanospheres: controllable synthesis and their 
surface modifications. J Mater Chem 2009, 19 (21), 3546-3553. 
90. Li, Z.; Zhang, Y., An efficient and user-friendly method for the synthesis of hexagonal-
phase NaYF(4):Yb, Er/Tm nanocrystals with controllable shape and upconversion fluorescence. 
Nanotechnology 2008, 19 (34), 345606. 
91. ML, S.; F, G., Microtubule assembly in the absence of added nucleotides. Proc Natl Acad 
Sci U S A. 1973, 70 (3), 765-8. 
92. Burkhart, C. A.; Kavallaris, M.; Horwitz, S. B., The role of beta-tubulin isotypes in 
resistance to antimitotic drugs. Bba-Rev Cancer 2001, 1471 (2), O1-O9. 
93. Kavallaris, M.; Kuo, D. Y.; Burkhart, C. A.; Regl, D. L.; Norris, M. D.; Haber, M.; 
Horwitz, S. B., Taxol-resistant epithelial ovarian tumors are associated with altered expression of 
specific beta-tubulin isotypes. The Journal of clinical investigation 1997, 100 (5), 1282-93. 
- 79 - 
 
94. Ferlini, C.; Cicchillitti, L.; Raspaglio, G.; Bartollino, S.; Cimitan, S.; Bertucci, C.; 
Mozzetti, S.; Gallo, D.; Persico, M.; Fattorusso, C.; Campiani, G.; Scambia, G., Paclitaxel 
directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res 2009, 69 (17), 
6906-14. 
95. Mackenzie, L. E.; Goode, J. A.; Vakurov, A.; Nampi, P. P.; Saha, S.; Jose, G.; Millner, P. 
A., The theoretical molecular weight of NaYF 4 :RE upconversion nanoparticles. Scientific 
reports 2018, 8 (1), 1106. 
96. Blajeski, A. L.; Phan, V. A.; Kottke, T. J.; Kaufmann, S. H., G(1) and G(2) cell-cycle 
arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 2002, 
110 (1), 91-9. 
97. Lv, X.; He, C.; Huang, C.; Hua, G.; Wang, Z.; Remmenga, S. W.; Rodabough, K. J.; 
Karpf, A. R.; Dong, J.; Davis, J. S.; Wang, C., G-1 Inhibits Breast Cancer Cell Growth via 
Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly. 
Molecular cancer therapeutics 2017, 16 (6), 1080-1091. 
98. Saoudi, Y.; Fotedar, R.; Abrieu, A.; Doree, M.; Wehland, J.; Margolis, R. L.; Job, D., 
Stepwise reconstitution of interphase microtubule dynamics in permeabilized cells and 
comparison to dynamic mechanisms in intact cells. The Journal of cell biology 1998, 142 (6), 
1519-32. 
99. Rai, A.; Surolia, A.; Panda, D., An antitubulin agent BCFMT inhibits proliferation of 
cancer cells and induces cell death by inhibiting microtubule dynamics. PloS one 2012, 7 (8), 
e44311. 
100. Duangmano, S.; Sae-lim, P.; Suksamrarn, A.; Domann, F. E.; Patmasiriwat, P., 
Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule 
polymerization and nucleophosmin/B23 translocation. Bmc Complem Altern M 2012, 12. 
- 80 - 
 
101. Abeylath, S. C.; Ganta, S.; Iyer, A. K.; Amiji, M., Combinatorial-designed 
multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery. Accounts of 
chemical research 2011, 44 (10), 1009-17. 
102. Caldorera-Moore, M. E.; Liechty, W. B.; Peppas, N. A., Responsive theranostic systems: 
integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. 
Accounts of chemical research 2011, 44 (10), 1061-70. 
103. Shi, J.; Xiao, Z.; Kamaly, N.; Farokhzad, O. C., Self-assembled targeted nanoparticles: 
evolution of technologies and bench to bedside translation. Accounts of chemical research 2011, 
44 (10), 1123-34. 
104. Koo, H.; Huh, M. S.; Sun, I. C.; Yuk, S. H.; Choi, K.; Kim, K.; Kwon, I. C., In vivo 
targeted delivery of nanoparticles for theranosis. Accounts of chemical research 2011, 44 (10), 
1018-28. 
105. Scott, A. M.; Wolchok, J. D.; Old, L. J., Antibody therapy of cancer. Nature reviews. 
Cancer 2012, 12 (4), 278-87. 
106. Loo, D. T.; Mather, J. P., Antibody-based identification of cell surface antigens: targets 
for cancer therapy. Curr Opin Pharmacol 2008, 8 (5), 627-631. 
107. Trikha, M.; Corringham, R.; Klein, B.; Rossi, J. F., Targeted anti-interleukin-6 
monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clinical 
cancer research : an official journal of the American Association for Cancer Research 2003, 9 
(13), 4653-65. 
108. Schrama, D.; Reisfeld, R. A.; Becker, J. C., Antibody targeted drugs as cancer 
therapeutics. Nat Rev Drug Discov 2006, 5 (2), 147-159. 
109. Milenic, D. E.; Brady, E. D.; Brechbiel, M. W., Antibody-targeted radiation cancer 
therapy. Nat Rev Drug Discov 2004, 3 (6), 488-99. 
- 81 - 
 
110. Srinivasarao, M.; Galliford, C. V.; Low, P. S., Principles in the design of ligand-targeted 
cancer therapeutics and imaging agents. Nat Rev Drug Discov 2015, 14 (3), 203-19. 
111. Hilgenbrink, A. R.; Low, P. S., Folate receptor-mediated drug targeting: from 
therapeutics to diagnostics. Journal of pharmaceutical sciences 2005, 94 (10), 2135-46. 
112. Paulos, C. M.; Turk, M. J.; Breur, G. J.; Low, P. S., Folate receptor-mediated targeting of 
therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Advanced drug 
delivery reviews 2004, 56 (8), 1205-17. 
113. Landmark, K. J.; DiMaggio, S.; Ward, J.; Kelly, C. V.; Vogt, S.; Hong, S.; Kotlyar, A.; 
Myc, A.; Thomas, T. P.; Penner-Hahn, J. E.; Baker, J. R.; Holl, M. M. B.; Orr, B. G., Synthesis, 
characterization, and in vitro testing of superparamagnetic iron oxide nanoparticles targeted 
using folic acid-conjugated dendrimers. Acs Nano 2008, 2 (4), 773-783. 
114. Fan, N. C.; Cheng, F. Y.; Ho, J. A. A.; Yeh, C. S., Photocontrolled Targeted Drug 
Delivery: Photocaged Biologically Active Folic Acid as a Light-Responsive Tumor-Targeting 
Molecule. Angew Chem Int Edit 2012, 51 (35), 8806-8810. 
115. Zuber, G.; Zammut-Italiano, L.; Dauty, E.; Behr, J. P., Targeted gene delivery to cancer 
cells: directed assembly of nanometric DNA particles coated with folic acid. Angewandte 
Chemie 2003, 42 (23), 2666-9. 
116. Cho, H. J.; Yoon, H. Y.; Koo, H.; Ko, S. H.; Shim, J. S.; Lee, J. H.; Kim, K.; Kwon, I. C.; 
Kim, D. D., Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and 
Pluronic(R) for tumor-targeted delivery of docetaxel. Biomaterials 2011, 32 (29), 7181-90. 
117. Lee, Y.; Lee, H.; Kim, Y. B.; Kim, J.; Hyeon, T.; Park, H.; Messersmith, P. B.; Park, T. 
G., Bioinspired Surface Immobilization of Hyaluronic Acid on Monodisperse Magnetite 
Nanocrystals for Targeted Cancer Imaging. Advanced materials 2008, 20 (21), 4154-4157. 
118. Jiang, T.; Zhang, Z.; Zhang, Y.; Lv, H.; Zhou, J.; Li, C.; Hou, L.; Zhang, Q., Dual-
functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for 
tumor-targeted anticancer drug delivery. Biomaterials 2012, 33 (36), 9246-58. 
- 82 - 
 
119. Li, J.; He, Y.; Sun, W.; Luo, Y.; Cai, H.; Pan, Y.; Shen, M.; Xia, J.; Shi, X., Hyaluronic 
acid-modified hydrothermally synthesized iron oxide nanoparticles for targeted tumor MR 
imaging. Biomaterials 2014, 35 (11), 3666-77. 
120. Chen, C.; Ke, J.; Zhou, X. E.; Yi, W.; Brunzelle, J. S.; Li, J.; Yong, E. L.; Xu, H. E.; 
Melcher, K., Structural basis for molecular recognition of folic acid by folate receptors. Nature 
2013, 500 (7463), 486-9. 
121. Mankoff, D. A.; Link, J. M.; Linden, H. M.; Sundararajan, L.; Krohn, K. A., Tumor 
receptor imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 
2008, 49 Suppl 2, 149S-63S. 
122. Zhao, X.; Li, H.; Lee, R. J., Targeted drug delivery via folate receptors. Expert opinion 
on drug delivery 2008, 5 (3), 309-19. 
123. Ahrens, T.; Assmann, V.; Fieber, C.; Termeer, C. C.; Herrlich, P.; Hofmann, M.; Simon, 
J. C., CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J 
Invest Dermatol 2001, 116 (1), 93-101. 
124. Collins, F. S.; Varmus, H., A new initiative on precision medicine. The New England 
journal of medicine 2015, 372 (9), 793-5. 
125. Schork, N. J., Personalized medicine: Time for one-person trials. Nature 2015, 520 
(7549), 609-11. 
126. Huang, X. H.; El-Sayed, I. H.; Qian, W.; El-Sayed, M. A., Cancer cell imaging and 
photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc 2006, 
128 (6), 2115-2120. 
127. Cho, S. K.; Emoto, K.; Su, L. J.; Yang, X.; Flaig, T. W.; Park, W., Functionalized gold 
nanorods for thermal ablation treatment of bladder cancer. Journal of biomedical 
nanotechnology 2014, 10 (7), 1267-76. 
- 83 - 
 
128. Cheng, Y.; Meyers, J. D.; Agnes, R. S.; Doane, T. L.; Kenney, M. E.; Broome, A. M.; 
Burda, C.; Basilion, J. P., Addressing brain tumors with targeted gold nanoparticles: a new gold 
standard for hydrophobic drug delivery? Small 2011, 7 (16), 2301-6. 
129. von Maltzahn, G.; Park, J. H.; Agrawal, A.; Bandaru, N. K.; Das, S. K.; Sailor, M. J.; 
Bhatia, S. N., Computationally Guided Photothermal Tumor Therapy Using Long-Circulating 
Gold Nanorod Antennas. Cancer Res 2009, 69 (9), 3892-3900. 
130. Arap, W.; Pasqualini, R.; Ruoslahti, E., Cancer treatment by targeted drug delivery to 
tumor vasculature in a mouse model. Science 1998, 279 (5349), 377-80. 
131. Du, B.; Han, H.; Wang, Z.; Kuang, L.; Wang, L.; Yu, L.; Wu, M.; Zhou, Z.; Qian, M., 
targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide. 
Molecular cancer research : MCR 2010, 8 (2), 135-44. 
132. Newton, J. R.; Kelly, K. A.; Mahmood, U.; Weissleder, R.; Deutscher, S. L., In vivo 
selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia 
2006, 8 (9), 772-80. 
133. Wang, T.; Hartner, W. C.; Gillespie, J. W.; Praveen, K. P.; Yang, S.; Mei, L. A.; Petrenko, 
V. A.; Torchilin, V. P., Enhanced tumor delivery and antitumor activity in vivo of liposomal 
doxorubicin modified with MCF-7-specific phage fusion protein. Nanomedicine : 
nanotechnology, biology, and medicine 2014, 10 (2), 421-30. 
134. Wang, T.; D'Souza, G. G.; Bedi, D.; Fagbohun, O. A.; Potturi, L. P.; Papahadjopoulos-
Sternberg, B.; Petrenko, V. A.; Torchilin, V. P., Enhanced binding and killing of target tumor 
cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. 
Nanomedicine (Lond) 2010, 5 (4), 563-74. 
135. Wang, T.; Petrenko, V. A.; Torchilin, V. P., Paclitaxel-loaded polymeric micelles 
modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and 
increased cytotoxicity. Molecular pharmaceutics 2010, 7 (4), 1007-14. 
- 84 - 
 
136. Wang, T.; Yang, S. H.; Petrenko, V. A.; Torchilin, V. P., Cytoplasmic Delivery of 
Liposomes into MCF-7 Breast Cancer Cells Mediated by Cell-Specific Phage Fusion Coat 
Protein. Molecular pharmaceutics 2010, 7 (4), 1149-1158. 
137. Lupp, A.; Danz, M.; Muller, D., Morphology and cytochrome P450 isoforms expression 
in precision-cut rat liver slices. Toxicology 2001, 161 (1-2), 53-66. 
138. Gusnard, D.; Kirschner, R. H., Cell and organelle shrinkage during preparation for 
scanning electron microscopy: effects of fixation, dehydration and critical point drying. J 
Microsc 1977, 110 (1), 51-7. 
  
- 85 - 
 
Appendix A: List of Abbreviations 
2D                           two-dimensional 
3D                           three-dimensional 
AFM                       atomic force microscope 
ALP                        alkaline phosphatase 
APD                       antibody phage display 
AuNRs                    gold nanorods 
CPD                        critical point drying 
CTAB                     cetyl trimethylammonium bromide  
CTP                         cell-targeting peptide 
Ctrl                          control 
DAPI                       4′,6-diamidino-2-phenylindole 
DLS                        dynamic light scattering 
DMEM                    dulbecco's modified eagle medium 
E. coli                      Escherichia coli          
EDC                        N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EDS                       energy-dispersive X-ray spectroscopy 
EGTA                    ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
ELISA                    enzyme-linked immunosorbent assay 
EMEM                   eagle’s minimal essential medium 
ER                           estrogen 
Ff                             filamentary bacteria phage 
HE                           haematoxylin and eosin 
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HRT                         hormone replacement therapy 
IC50                         half maximal inhibitory concentration 
ICP-AES                 inductively coupled plasma atomic emission spectroscopy 
IGEPAL CO-520     polyoxyethylene (5) nonylphenylether, 
LB                           lysogeny broth 
mAb                         monoclonal antibody 
mPEG-Silane           methosy polyethyleneglycol-silane 
MES                          2-(N-morpholino) ethanesulfonic acid 
MT                             microtubule 
MW                           molecular weight 
NHS                           N-Hydroxysuccinimide 
NIR                            near-infrared 
OD                              optical density 
ODE                           1-octadecene 
pNPP                           p-nitrophenyl phosphate 
PBS                             phosphate buffered saline 
PEG                             polyethyleneglycol 
PFA                             paraformaldehyde 
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PIPES                          1,4-piperazinediethanesulfonic acid 
Rd                                round 
SEM                           scanning electron microscope 
Silane-PEG-COOH     silane-polyethyleneglycol-acetic acid 
TEM                            transmission electron microscope 
TEOS                           tetraethoxysilane 
TIP                               tubulin-interactive peptide 
TU                               transducing units 
UCNP                          up-converting nano-particle 
U. S.                             United States 
UV                                ultraviolet 
V                                   volume  
WT                                 wild type 
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